☰

Osamu Ogawa - Publications

Affiliations: 
 
Area:
http://www.biomedexperts.com/Profile.bme/1040896/NN
Tree Info Grants Similar researchers PubMed Report error

12/500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2008 Zhu X, Wang Y, Ogawa O, Lee HG, Raina AK, Fujioka H, Shimohama S, Atwood CS, Petersen RB, Perry G, Smith MA. Oral Presentations OP01: Neurodegenerative Diseases Journal of Neurochemistry. 81: 76-76. DOI: 10.1046/J.1471-4159.81.S1.44_1.X  0.468
2004 Zhu X, Wang Y, Ogawa O, Lee HG, Raina AK, Siedlak SL, Harris PL, Fujioka H, Shimohama S, Tabaton M, Atwood CS, Petersen RB, Perry G, Smith MA. Neuroprotective properties of Bcl-w in Alzheimer disease. Journal of Neurochemistry. 89: 1233-40. PMID 15147516 DOI: 10.1111/J.1471-4159.2004.02416.X  0.468
2004 Lee HG, Ogawa O, Zhu X, O'Neill MJ, Petersen RB, Castellani RJ, Ghanbari H, Perry G, Smith MA. Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer's disease. Acta Neuropathologica. 107: 365-71. PMID 14872255 DOI: 10.1007/S00401-004-0820-8  0.457
2004 Casadesus G, Webber KM, Ogawa O, Bowen RL, Atwood CS, Perry G, Smith MA. P1-369 Modulation of cognition and amyloid load in the aged SWAβPP transgenic mouse by luprolide acetate, a GNRH agonist: targeting luteinizing hormone as a novel treatment for AD Neurobiology of Aging. 25: S203. DOI: 10.1016/S0197-4580(04)80681-X  0.392
2003 Ogawa O, Lee HG, Zhu X, Raina A, Harris PL, Castellani RJ, Perry G, Smith MA. Increased p27, an essential component of cell cycle control, in Alzheimer's disease. Aging Cell. 2: 105-10. PMID 12882323 DOI: 10.1046/J.1474-9728.2003.00042.X  0.46
2003 Ogawa O, Zhu X, Lee HG, Raina A, Obrenovich ME, Bowser R, Ghanbari HA, Castellani RJ, Perry G, Smith MA. Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: a mitotic catastrophe? Acta Neuropathologica. 105: 524-8. PMID 12677454 DOI: 10.1007/S00401-003-0684-3  0.445
2003 Raina AK, Hochman A, Ickes H, Zhu X, Ogawa O, Cash AD, Shimohama S, Perry G, Smith MA. Apoptotic promoters and inhibitors in Alzheimer's disease: Who wins out? Progress in Neuro-Psychopharmacology & Biological Psychiatry. 27: 251-4. PMID 12657364 DOI: 10.1016/S0278-5846(03)00020-4  0.455
2003 Zhu X, Ogawa O, Wang Y, Perry G, Smith MA. JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer's disease. Journal of Neurochemistry. 85: 87-93. PMID 12641730 DOI: 10.1046/J.1471-4159.2003.01645.X  0.454
2002 Ogawa O, Zhu X, Perry G, Smith MA. Mitochondrial abnormalities and oxidative imbalance in neurodegenerative disease. Science of Aging Knowledge Environment : Sage Ke. 2002: pe16. PMID 14603007 DOI: 10.1126/Sageke.2002.41.Pe16  0.39
2002 Lee HG, Zhu X, Ghanbari HA, Ogawa O, Raina AK, O'Neill MJ, Perry G, Smith MA. Differential regulation of glutamate receptors in Alzheimer's disease. Neuro-Signals. 11: 282-92. PMID 12566929 DOI: 10.1159/000067427  0.435
2002 Cash AD, Perry G, Ogawa O, Raina AK, Zhu X, Smith MA. Is Alzheimer's disease a mitochondrial disorder? The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry. 8: 489-96. PMID 12374431 DOI: 10.1177/107385802236968  0.449
2002 Ogawa O, Perry G, Smith MA. The "Down's" side of mitochondria. Developmental Cell. 2: 255-6. PMID 11879629 DOI: 10.1016/S1534-5807(02)00139-9  0.44
Low-probability matches (unlikely to be authored by this person)
2019 Inoue T, Kobayashi T, Terada N, Shimizu Y, Kamoto T, Ogawa O, Nakamura E. Roles of androgen-dependent and -independent activation of signal transduction pathways for cell proliferation of prostate cancer cells. Expert Review of Endocrinology & Metabolism. 2: 689-704. PMID 30736131 DOI: 10.1586/17446651.2.5.689  0.217
2010 Kobayashi T, Inoue T, Shimizu Y, Terada N, Maeno A, Kajita Y, Yamasaki T, Kamba T, Toda Y, Mikami Y, Yamada T, Kamoto T, Ogawa O, Nakamura E. Activation of Rac1 is closely related to androgen-independent cell proliferation of prostate cancer cells both in vitro and in vivo. Molecular Endocrinology (Baltimore, Md.). 24: 722-34. PMID 20203103 DOI: 10.1210/me.2009-0326  0.215
2022 Miyazaki Y, Goto T, Li X, Nakayama K, Okasho K, Takeda M, Mizuno K, Kimura H, Uegaki M, Sumiyoshi T, Teramoto Y, Akamatsu S, Kobayashi T, Ogawa O, Inoue T. Up-regulation of secretory leukocyte protease inhibitor in human samples might have a potential role of predicting prostate cancer recurrence and progression after surgery and hormonal therapy. Cancer Medicine. 12: 3328-3342. PMID 36812122 DOI: 10.1002/cam4.5134  0.213
2011 Xing ND, Ding ST, Saito R, Nishizawa K, Kobayashi T, Inoue T, Oishi S, Fujii N, Lv JJ, Ogawa O, Nishiyama H. A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor. Asian Journal of Andrology. 13: 236-41. PMID 21297652 DOI: 10.1038/aja.2010.171  0.212
2014 Onozawa M, Hinotsu S, Tsukamoto T, Oya M, Ogawa O, Kitamura T, Suzuki K, Naito S, Namiki M, Nishimura K, Hirao Y, Akaza H. Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan. Japanese Journal of Clinical Oncology. 44: 969-81. PMID 25098707 DOI: 10.1093/Jjco/Hyu104  0.207
2011 Inoue T, Ogawa O. Role of signaling transduction pathways in development of castration-resistant prostate cancer. Prostate Cancer. 2011: 647987. PMID 22110995 DOI: 10.1155/2011/647987  0.204
2009 Wang W, Yuasa T, Tsuchiya N, Ma Z, Maita S, Narita S, Kumazawa T, Inoue T, Tsuruta H, Horikawa Y, Saito M, Hu W, Ogawa O, Habuchi T. The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression and clinical significance. International Journal of Cancer. Journal International Du Cancer. 125: 2836-43. PMID 19585577 DOI: 10.1002/ijc.24721  0.202
2014 Xu S, Zhang Z, Ogawa O, Yoshikawa T, Sakamoto H, Shibasaki N, Goto T, Wang L, Terada N. An EP4 antagonist ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer. Cell Biochemistry and Biophysics. 70: 521-7. PMID 24744183 DOI: 10.1007/s12013-014-9951-2  0.197
2019 Miyazaki Y, Teramoto Y, Shibuya S, Goto T, Okasho K, Mizuno K, Uegaki M, Yoshikawa T, Akamatsu S, Kobayashi T, Ogawa O, Inoue T. Consecutive Prostate Cancer Specimens Revealed Increased Aldo⁻Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer. Journal of Clinical Medicine. 8. PMID 31052459 DOI: 10.3390/jcm8050601  0.197
2004 Kumazawa T, Tsuchiya N, Wang L, Sato K, Kamoto T, Ogawa O, Nakamura A, Kato T, Habuchi T. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer. International Journal of Cancer. Journal International Du Cancer. 110: 140-4. PMID 15054879 DOI: 10.1002/ijc.20070  0.197
2018 Akamatsu S, Inoue T, Ogawa O, Gleave ME. Clinical and molecular features of treatment-related neuroendocrine prostate cancer. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 29396873 DOI: 10.1111/iju.13526  0.196
2021 Okasho K, Ogawa O, Akamatsu S. Narrative review of challenges in the management of advanced neuroendocrine prostate cancer. Translational Andrology and Urology. 10: 3953-3962. PMID 34804838 DOI: 10.21037/tau-20-1131  0.196
2014 Kobayashi T, Ogawa O. [Genetic analysis in prostate cancer]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 72: 2217-23. PMID 25518361  0.195
2010 Terada N, Shimizu Y, Kamba T, Inoue T, Maeno A, Kobayashi T, Nakamura E, Kamoto T, Kanaji T, Maruyama T, Mikami Y, Toda Y, Matsuoka T, Okuno Y, Tsujimoto G, ... ... Ogawa O, et al. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Research. 70: 1606-15. PMID 20145136 DOI: 10.1158/0008-5472.CAN-09-2984  0.195
2022 Shimizu K, Sano T, Mizuno K, Sunada T, Makita N, Hagimoto H, Goto T, Sawada A, Fujimoto M, Ichioka K, Ogawa O, Kobayashi T, Akamatsu S. A case of microsatellite instability-high clinically advanced castration-resistant prostate cancer showing a remarkable response to pembrolizumab sustained over at least 18 months. Cold Spring Harbor Molecular Case Studies. PMID 35487690 DOI: 10.1101/mcs.a006194  0.193
2002 Fujiwara H, Emi M, Nagai H, Nishimura T, Konishi N, Kubota Y, Ichikawa T, Takahashi S, Shuin T, Habuchi T, Ogawa O, Inoue K, Skolnick MH, Swensen J, Camp NJ, et al. Association of common missense changes in ELAC2 ( HPC2) with prostate cancer in a Japanese case-control series. Journal of Human Genetics. 47: 641-8. PMID 12522685 DOI: 10.1007/S100380200099  0.192
1998 Ogawa O, Egawa S, Arai Y, Tobisu K, Yoshida O, Kato T. Preoperative predictors for organ-confined disease in Japanese patients with stage T1c prostate cancer. International Journal of Urology : Official Journal of the Japanese Urological Association. 5: 454-8. PMID 9781434 DOI: 10.1111/j.1442-2042.1998.tb00387.x  0.191
2017 Terada N, Akamatsu S, Kobayashi T, Inoue T, Ogawa O, Antonarakis ES. Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Therapeutic Advances in Medical Oncology. 9: 565-573. PMID 28794807 DOI: 10.1177/1758834017719215  0.191
2005 Kamoto T, Isogawa Y, Shimizu Y, Minamiguchi S, Kinoshita H, Kakehi Y, Mitsumori K, Yamamoto S, Habuchi T, Kato T, Ogawa O. Association of a genetic polymorphism of the E-cadherin gene with prostate cancer in a Japanese population. Japanese Journal of Clinical Oncology. 35: 158-61. PMID 15741307 DOI: 10.1093/JJCO/HYI040  0.19
2019 Uegaki M, Kita Y, Shirakawa R, Teramoto Y, Kamiyama Y, Saito R, Yoshikawa T, Sakamoto H, Goto T, Akamatsu S, Yamasaki T, Inoue T, Suzuki A, Horiuchi H, Ogawa O, et al. Downregulation of RalGTPase-activating protein promotes invasion of prostatic epithelial cells and progression from intraepithelial neoplasia to cancer during prostate carcinogenesis. Carcinogenesis. PMID 31058283 DOI: 10.1093/carcin/bgz082  0.19
2014 Inamoto T, Azuma H, Hinotsu S, Tsukamoto T, Oya M, Ogawa O, Kitamura T, Kazuhiro S, Naito S, Namiki M, Nishimura K, Hirao Y, Usami M, Murai M, Akaza H, et al. Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice: results from Japanese observational cohort. Journal of Cancer Research and Clinical Oncology. 140: 1197-204. PMID 24676427 DOI: 10.1007/S00432-014-1638-Y  0.189
2007 Fukuda H, Tsuchiya N, Narita S, Kumazawa T, Horikawa Y, Inoue T, Saito M, Yuasa T, Matsuura S, Satoh S, Ogawa O, Habuchi T. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer. Oncology Reports. 18: 1155-63. PMID 17914566  0.189
2005 Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, Kamoto T, Ogawa O. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Research. 65: 9611-6. PMID 16266977 DOI: 10.1158/0008-5472.CAN-05-0817  0.189
2005 Maeda H, Hori S, Ohizumi H, Segawa T, Kakehi Y, Ogawa O, Kakizuka A. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death and Differentiation. 11: 737-46. PMID 15002036 DOI: 10.1038/sj.cdd.4401389  0.189
2010 Kobayashi T, Shimizu Y, Terada N, Yamasaki T, Nakamura E, Toda Y, Nishiyama H, Kamoto T, Ogawa O, Inoue T. Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation. The Prostate. 70: 866-74. PMID 20127734 DOI: 10.1002/pros.21120  0.188
2002 Wu XX, Kakehi Y, Mizutani Y, Kamoto T, Kinoshita H, Isogawa Y, Terachi T, Ogawa O. Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. International Journal of Oncology. 20: 949-54. PMID 11956588  0.188
1995 Wu WJ, Kakehi Y, Habuchi T, Kinoshita H, Ogawa O, Terachi T, Huang CH, Chiang CP, Yoshida O. Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Japanese Journal of Cancer Research : Gann. 86: 730-6. PMID 7559095 DOI: 10.1111/j.1349-7006.1995.tb02461.x  0.188
2014 Terada N, Inoue T, Kamba T, Ogawa O. [Novel treatment for prostate cancer targeting prostaglandins]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 72: 2141-6. PMID 25518348  0.188
2017 Okada Y, Sonoshita M, Kakizaki F, Aoyama N, Itatani Y, Uegaki M, Sakamoto H, Kobayashi T, Inoue T, Kamba T, Suzuki A, Ogawa O, Taketo MM. Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer. Cancer Science. PMID 28178391 DOI: 10.1111/Cas.13187  0.188
2006 Tsuchiya N, Wang L, Suzuki H, Segawa T, Fukuda H, Narita S, Shimbo M, Kamoto T, Mitsumori K, Ichikawa T, Ogawa O, Nakamura A, Habuchi T. Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 1982-9. PMID 16648498 DOI: 10.1200/JCO.2005.02.9439  0.187
2018 Nakamura K, Ikeda I, Inokuchi H, Takayama K, Inoue T, Kamba T, Ogawa O, Hiraoka M, Mizowaki T. A pilot study of highly hypofractionated intensity-modulated radiation therapy over 3 weeks for localized prostate cancer. Journal of Radiation Research. PMID 30085048 DOI: 10.1093/jrr/rry060  0.187
2016 Yoshikawa T, Kobori G, Goto T, Akamatsu S, Terada N, Kobayashi T, Tanaka Y, Jung G, Kamba T, Ogawa O, Inoue T. An original patient-derived xenograft of prostate cancer with cyst formation. The Prostate. PMID 27098584 DOI: 10.1002/pros.23188  0.186
2009 Inoue T, Maeno A, Talbot C, Zeng Y, Yeater DB, Leman ES, Kulkarni P, Ogawa O, Getzenberg RH. Purine-rich element binding protein (PUR) alpha induces endoplasmic reticulum stress response, and cell differentiation pathways in prostate cancer cells. The Prostate. 69: 861-73. PMID 19267365 DOI: 10.1002/Pros.20936  0.186
2009 Kobayashi T, Nakamura E, Shimizu Y, Terada N, Maeno A, Kobori G, Kamba T, Kamoto T, Ogawa O, Inoue T. Restoration of cyclin D2 has an inhibitory potential on the proliferation of LNCaP cells. Biochemical and Biophysical Research Communications. 387: 196-201. PMID 19577536 DOI: 10.1016/j.bbrc.2009.06.146  0.186
2018 Nakamura K, Inokuchi H, Ikeda I, Kamba T, Inoue T, Yamasaki T, Kobayashi T, Ogawa O, Mizowaki T. Pilot study of moderately-hypofractionated intensity-modulated radiation therapy over 3 weeks for localized prostate cancer. Journal of Clinical Oncology. 36: 8-8. DOI: 10.1200/JCO.2018.36.6_SUPPL.8  0.186
2011 Shimizu Y, Hamazaki Y, Hattori M, Doi K, Terada N, Kobayashi T, Toda Y, Yamasaki T, Inoue T, Kajita Y, Maeno A, Kamba T, Mikami Y, Kamoto T, Yamada T, ... ... Ogawa O, et al. SPA-1 controls the invasion and metastasis of human prostate cancer. Cancer Science. 102: 828-36. PMID 21251160 DOI: 10.1111/j.1349-7006.2011.01876.x  0.186
2013 Kobayashi T, Inoue T, Kamba T, Ogawa O. Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer. International Journal of Molecular Sciences. 14: 15615-35. PMID 23896594 DOI: 10.3390/ijms140815615  0.186
2015 Nakamura K, Terada N, Kobayashi T, Sugino Y, Yamasaki T, Matsui Y, Imamura M, Okubo K, Kamba T, Yoshimura K, Ogawa O. [Clinical Characteristics of Prostate Ductal Adenocarcinoma in Kyoto University Hospital]. Hinyokika Kiyo. Acta Urologica Japonica. 61: 487-91. PMID 26790762  0.185
2021 Okasho K, Mizuno K, Fukui T, Lin YY, Kamiyama Y, Sunada T, Li X, Kimura H, Sumiyoshi T, Goto T, Kobayashi T, Lin D, Wang Y, Collins CC, Inoue T, ... Ogawa O, et al. Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13. Cancer Science. PMID 33960594 DOI: 10.1111/cas.14935  0.184
2005 Inoue T, Segawa T, Shiraishi T, Yoshida T, Toda Y, Yamada T, Kinukawa N, Kinoshita H, Kamoto T, Ogawa O. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology. 66: 332-7. PMID 16098362 DOI: 10.1016/j.urology.2005.02.028  0.184
2012 Kato K, Inoue T, Mizowaki T, Kamoto T, Kamba T, Shimizu Y, Norihisa Y, Yamada T, Hiraoka M, Yoshimura K, Ogawa O. [Salvage hormonal therapy against recurrence after curative external beam radiotherapy for locally advanced prostate cancer at Kyoto University Hospital]. Hinyokika Kiyo. Acta Urologica Japonica. 58: 599-603. PMID 23254783  0.184
2008 Naito S, Kuroiwa K, Kinukawa N, Goto K, Koga H, Ogawa O, Murai M, Shiraishi T. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer. The Journal of Urology. 180: 904-9; discussion 90. PMID 18635221 DOI: 10.1016/j.juro.2008.05.047  0.184
2008 Kobayashi T, Inoue T, Terada N, Shimizu Y, Yamasaki T, Kamoto T, Ogawa O, Nakamura E. ANDROGEN-DEPENDENT REGULATION OF PROTEIN KINASE Cζ AND ITS ROLES FOR PROGRESSION TO ANDROGEN INDEPENDENCY IN PROSTATE CANCER CELLS European Urology Supplements. 7: 310. DOI: 10.1016/S1569-9056(08)60954-9  0.183
2003 Wang L, Habuchi T, Tsuchiya N, Mitsumori K, Ohyama C, Sato K, Kinoshita H, Kamoto T, Nakamura A, Ogawa O, Kato T. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Research. 63: 4407-11. PMID 12907612  0.183
2003 Li Z, Habuchi T, Tsuchiya N, Mitsumori K, Wang L, Ohyama C, Sato K, Kamoto T, Ogawa O, Kato T. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10. Carcinogenesis. 25: 237-40. PMID 14604900 DOI: 10.1093/CARCIN/BGG197  0.183
2014 Mizuno K, Inoue T, Miyazaki Y, Makino Y, Terada N, Kobayashi T, Yamasaki T, Matsui Y, Kamba T, Yoshimura K, Mikami Y, Ogawa O. [Development of a preoperative criterion to select candidates for nerve-sparing radical prostatectomy at Kyoto University Hospital]. Hinyokika Kiyo. Acta Urologica Japonica. 60: 543-7. PMID 25511940  0.183
2009 Kobayashi T, Inoue T, Shimizu Y, Terada N, Maeno A, Kamba T, Kamoto T, Ogawa O, Nakamura E. 509 UPSTREAM REGULATORS FOR ANDROGEN-DEPENDENT ACTIVATION OF ATYPICAL PROTEIN KINASE C IN PROSTATE CANCER CELLS AND THEIR ROLES FOR ANDROGEN-INDEPENDENT PROGRESSION European Urology Supplements. 8: 248. DOI: 10.1016/S1569-9056(09)60505-4  0.183
2006 Inoue T, Yoshida T, Shimizu Y, Kobayashi T, Yamasaki T, Toda Y, Segawa T, Kamoto T, Nakamura E, Ogawa O. Requirement of androgen-dependent activation of protein kinase Czeta for androgen-dependent cell proliferation in LNCaP Cells and its roles in transition to androgen-independent cells. Molecular Endocrinology (Baltimore, Md.). 20: 3053-69. PMID 16931574 DOI: 10.1210/me.2006-0033  0.182
1999 Ogawa O, Iinuma M, Sato K, Sasaki R, Shimoda N, Satoh S, Kato T. Circulating prostate-specific antigen mRNA during radical prostatectomy in patients with localized prostate cancer: with special reference to neoadjuvant hormonal therapy. Urological Research. 27: 291-6. PMID 10460902 DOI: 10.1007/s002400050126  0.182
2006 Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Hirao Y, Murai M, Yamanaka H, Namiki M. The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. The Journal of Urology. 176: S47-9. PMID 17084166 DOI: 10.1016/j.juro.2006.06.070  0.182
2006 Inoue T, Nakamura E, Yoshida T, Shimizu Y, Kobayashi T, Segawa T, Kamoto T, Ogawa O. 424: Androgen Dependent Activation of Protein Kinase Cζ and its Roles of Androgen-Independent Cell Proliferation in Prostate Cancer Cells Journal of Urology. 175: 138-138. DOI: 10.1016/s0022-5347(18)32680-6  0.181
2020 Aizawa R, Takayama K, Nakamura K, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Ogawa O, Mizowaki T. Increased risk of disease progression in younger men: Analysis of factors predicting biochemical failure and castration-resistant prostate cancer after high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer. Urologic Oncology. PMID 33127301 DOI: 10.1016/j.urolonc.2020.09.026  0.181
2004 Narita S, Tsuchiya N, Wang L, Matsuura S, Ohyama C, Satoh S, Sato K, Ogawa O, Habuchi T, Kato T. Association of lipoprotein lipase gene polymorphism with risk of prostate cancer in a Japanese population. International Journal of Cancer. 112: 872-6. PMID 15386377 DOI: 10.1002/ijc.20477  0.18
2005 Shioji G, Ezura Y, Nakajima T, Ohgaki K, Fujiwara H, Kubota Y, Ichikawa T, Inoue K, Shuin T, Habuchi T, Ogawa O, Nishimura T, Emi M. Nucleotide variations in genes encoding plasminogen activator inhibitor-2 and serine proteinase inhibitor B10 associated with prostate cancer. Journal of Human Genetics. 50: 507-15. PMID 16172807 DOI: 10.1007/s10038-005-0285-1  0.18
2008 Narita N, Yuasa T, Tsuchiya N, Kumazawa T, Narita S, Inoue T, Ma Z, Saito M, Horikawa Y, Satoh S, Ogawa O, Habuchi T. A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer. Bmc Cancer. 8: 224. PMID 18684318 DOI: 10.1186/1471-2407-8-224  0.178
2005 Tsuchiya N, Wang L, Horikawa Y, Inoue T, Kakinuma H, Matsuura S, Sato K, Ogawa O, Kato T, Habuchi T. CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia. International Journal of Oncology. 26: 225-31. PMID 15586244  0.177
2012 Hinotsu S, Akaza H, Ogawa O, Oya M, Kitamura T, Suzuki K, Tsukamoto T, Naito S, Namiki M, Nishimura K, Hirao Y. Hormonal therapy for localized prostate cancer in Japan: The outcome of J-CaP database. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 54. PMID 27967865 DOI: 10.1200/Jco.2012.30.5_Suppl.54  0.177
2014 Maeno A, Terada N, Uegaki M, Goto T, Okada Y, Kobayashi T, Kamba T, Ogawa O, Inoue T. Up-regulation of miR-582-5p regulates cellular proliferation of prostate cancer cells under androgen-deprived conditions. The Prostate. 74: 1604-12. PMID 25176332 DOI: 10.1002/pros.22877  0.176
2004 Nakashima M, Nishiyama H, Yagihashi Y, Yamamoto S, Kamoto T, Habuchi T, Ogawa O. [A case report of a young patient with invasive bladder cancer]. Hinyokika Kiyo. Acta Urologica Japonica. 49: 745-8. PMID 14978958  0.176
2015 Sunada T, Kobayashi T, Shibasaki N, Okada Y, Negoro H, Terada N, Yamasaki T, Matsui Y, Inoue T, Kamba T, Ogawa O. [A Case of Rapidly Progressive Metastatic Castration-Resistant Prostate Cancer : Durable Control by Early Induction of Carboplatin and Paclitaxel]. Hinyokika Kiyo. Acta Urologica Japonica. 61: 369-73. PMID 26497864  0.176
2005 Zhenhua L, Tsuchiya N, Narita S, Inoue T, Horikawa Y, Kakinuma H, Kato T, Ogawa O, Habuchi T. CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population. Cancer Letters. 225: 237-43. PMID 15876487 DOI: 10.1016/j.canlet.2005.03.009  0.176
2012 Li B, Shimizu Y, Kobayashi T, Terada N, Yoshimura K, Kamba T, Mikami Y, Inoue T, Nishiyama H, Ogawa O. Overexpression of ETS-1 is associated with malignant biological features of prostate cancer. Asian Journal of Andrology. 14: 860-3. PMID 23064684 DOI: 10.1038/aja.2012.107  0.176
2007 Shimizu Y, Segawa T, Inoue T, Shiraishi T, Yoshida T, Toda Y, Yamada T, Kinukawa N, Terada N, Kobayashi T, Kinoshita H, Kamoto T, Nakamura E, Ogawa O. Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. Bju International. 100: 685-90. PMID 17542985 DOI: 10.1111/j.1464-410X.2007.07014.x  0.175
2004 Akaza H, Naito S, Chang SJ, Chen KK, Cheng C, Choi HY, Fujioka T, Hinotsu S, Hirao Y, Hong SJ, Kim CS, Kim WJ, Lee SE, Murai M, Ogawa O, et al. The 3rd Conference on Asian Trends in Prostate Cancer Hormone Therapy. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 31: 1285-95. PMID 15332559  0.175
2000 Maeda H, Segawa T, Kamoto T, Yoshida H, Kakizuka A, Ogawa O, Kakehi Y. Rapid detection of candidate metastatic foci in the orthotopic inoculation model of androgen-sensitive prostate cancer cells introduced with green fluorescent protein. The Prostate. 45: 335-40. PMID 11102959 DOI: 10.1002/1097-0045(20001201)45:4<335::AID-PROS8>3.0.CO;2-O  0.175
2012 Nguyen HH, Takata R, Akamatsu S, Shigemizu D, Tsunoda T, Furihata M, Takahashi A, Kubo M, Kamatani N, Ogawa O, Fujioka T, Nakamura Y, Nakagawa H. IRX4 at 5p15 suppresses prostate cancer growth through the interaction with vitamin D receptor, conferring prostate cancer susceptibility. Human Molecular Genetics. 21: 2076-85. PMID 22323358 DOI: 10.1093/hmg/dds025  0.174
2007 Matsui Y, Ueda S, Watanabe J, Kuwabara I, Ogawa O, Nishiyama H. Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species. Cancer Research. 67: 1212-20. PMID 17283157 DOI: 10.1158/0008-5472.CAN-06-3283  0.174
2022 Makino Y, Kamiyama Y, Brown JB, Tanaka T, Murakami R, Teramoto Y, Goto T, Akamatsu S, Terada N, Inoue T, Kodama T, Ogawa O, Kobayashi T. Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1. Communications Biology. 5: 299. PMID 35365763 DOI: 10.1038/s42003-022-03227-w  0.174
2022 Nagai T, Terada N, Fujii M, Nagata Y, Nakahara K, Mukai S, Okasho K, Kamiyama Y, Akamatsu S, Kobayashi T, Iida K, Denawa M, Hagiwara M, Inoue T, Ogawa O, et al. Identification of the α2 chain of interleukin-13 receptor as a potential biomarker for predicting castration resistance of prostate cancer using patient-derived xenograft models. Cancer Reports (Hoboken, N.J.). 6: e1701. PMID 36806727 DOI: 10.1002/cnr2.1701  0.174
2009 Inoue T, Segawa T, Kamba T, Yoshimura K, Nakamura E, Nishiyama H, Ito N, Kamoto T, Habuchi T, Ogawa O. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan. Urology. 73: 1104-9. PMID 19394511 DOI: 10.1016/j.urology.2008.07.062  0.174
1998 Fujikawa K, Sasaki M, Itoh T, Arai Y, Ogawa O, Yoshida O. Combining volume-weighted mean nuclear volume with Gleason score and clinical stage to predict more reliably disease outcome of patients with prostate cancer. The Prostate. 37: 63-9. PMID 9759699 DOI: 10.1002/(SICI)1097-0045(19981001)37:2<63::AID-PROS1>3.0.CO;2-M  0.174
2012 Saito R, Kobayashi T, Nakashima M, Matsui Y, Shibasaki N, Kanno T, Inoue T, Nishiyama H, Shirakawa R, Horiuchi H, Ogawa O. 839 RalGAP, the inactivator of Ral small GTPase, suppresses the progression of prostate cancer European Urology Supplements. 11: e839-e839a. DOI: 10.1016/S1569-9056(12)60836-7  0.174
2005 Inoue T, Nakamura E, Yoshida T, Shimizu Y, Segawa T, Kamoto T, Ogawa O. 247: The Role of F70 S6K Pathways in the Progression to Androgen Independent Cell Proliferation in Prostate Cancer Cells Journal of Urology. 173: 68-68. DOI: 10.1016/S0022-5347(18)34512-9  0.174
2009 Okamura M, Kamba T, Kanematsu A, Watanabe J, Shimizu T, Soda T, Yoshimura K, Nakamura E, Nishiyama H, Kamoto T, Ogawa O. [A case of elderly donor in living kidney transplant after radical radiotherapy for prostate cancer]. Hinyokika Kiyo. Acta Urologica Japonica. 55: 623-5. PMID 19926948  0.174
2009 Ma Z, Tsuchiya N, Yuasa T, Narita S, Horikawa Y, Kumazawa T, Saito M, Obara T, Tsuruta H, Kawata N, Satoh S, Ogawa O, Habuchi T. INFLUENCE OF POLYMORPHISMS AND EXPRESSION OF CHROMOGRANIN A AND ENDOTHELIN-1 ON THE DEVELOPMENT AND PROGRESSION OF PROSTATE CANCER Journal of Urology. 181: 49-50. DOI: 10.1016/S0022-5347(09)60151-8  0.174
2008 Ma Z, Tsuchiya N, Yuasa T, Inoue T, Kumazawa T, Narita S, Horikawa Y, Tsuruta H, Obara T, Saito M, Satoh S, Ogawa O, Habuchi T. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. International Journal of Cancer. Journal International Du Cancer. 123: 2574-9. PMID 18756523 DOI: 10.1002/ijc.23578  0.173
2005 Sawada A, Segawa T, Nakanishi S, Kinoshita H, Yamamoto S, Kamoto T, Ogawa O. [Prostate cancer with penile metastasis: a case report]. Hinyokika Kiyo. Acta Urologica Japonica. 51: 771-3. PMID 16363713  0.173
2022 Ueda M, Kono J, Sengiku A, Nagumo Y, Mathis BJ, Shimba S, Taketo MM, Kobayashi T, Ogawa O, Negoro H. Bmal1 Regulates Prostate Growth via Cell-Cycle Modulation. International Journal of Molecular Sciences. 23. PMID 36232573 DOI: 10.3390/ijms231911272  0.173
2007 Shimizu Y, Yoshida T, Segawa T, Inoue T, Kobayashi T, Terada N, Nakamura E, Kinoshita H, Kamoto T, Ogawa O. MP-17.12: Bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient Urology. 70: 133. DOI: 10.1016/J.UROLOGY.2007.06.497  0.172
2004 Ito Y, Nishiyama H, Higashi S, Kinoshita H, Ito N, Yamamoto S, Kamoto T, Ogawa O. [Transitional cell carcinoma in prostate after intravesical instillation of Bacillus Calmette-Guerin]. Hinyokika Kiyo. Acta Urologica Japonica. 50: 335-8. PMID 15237488  0.172
2012 Akamatsu S, Takata R, Haiman CA, Takahashi A, Inoue T, Kubo M, Furihata M, Kamatani N, Inazawa J, Chen GK, Le Marchand L, Kolonel LN, Katoh T, Yamano Y, Yamakado M, ... ... Ogawa O, et al. Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nature Genetics. 44: 426-9, S1. PMID 22366784 DOI: 10.1038/Ng.1104  0.171
2020 Takamori H, Kamba T, Sumiyoshi S, Tsuzuki T, Kashima S, Yoshino T, Sano T, Goto T, Sawada A, Akamatsu S, Kobayashi T, Yamasaki T, Mizowaki T, Ogawa O, Inoue T. Solitary recurrence of prostate cancer surrounded by seminal vesicle/vas deferens-like epithelium. Iju Case Reports. 3: 171-173. PMID 32914063 DOI: 10.1002/iju5.12168  0.171
2014 Nakayama K, Inoue T, Sekiya S, Terada N, Miyazaki Y, Goto T, Kajihara S, Kawabata S, Iwamoto S, Ikawa K, Oosaga J, Tsuji H, Tanaka K, Ogawa O. The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer. Plos One. 9: e107234. PMID 25233230 DOI: 10.1371/Journal.Pone.0107234  0.17
2004 Wang LZ, Sato K, Tsuchiya N, Yu JG, Ohyama C, Satoh S, Habuchi T, Ogawa O, Kato T. Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population. Cancer Letters. 202: 53-9. PMID 14643026 DOI: 10.1016/J.CANLET.2003.08.001  0.17
2004 Wu XX, Ogawa O, Kakehi Y. TRAIL and chemotherapeutic drugs in cancer therapy. Vitamins and Hormones. 67: 365-83. PMID 15110186 DOI: 10.1016/S0083-6729(04)67019-1  0.17
2018 Sumiyoshi T, Akamatsu S, Yamasaki T, Mizuno K, Goto T, Terada N, Kobayashi T, Inoue T, Kamba T, Fujimoto A, Ogawa O. MP29-05 ANDROGEN RECEPTOR GENE ABERRATIONS IN CIRCULATING CELL FREE DNA FROM JAPANESE CASTRATION RESISTANT PROSTATE CANCER PATIENTS Journal of Urology. 199. DOI: 10.1016/j.juro.2018.02.925  0.17
2021 Murakami K, Kita Y, Sakatani T, Hamada A, Mizuno K, Nakamura K, Takada H, Matsumoto K, Sano T, Goto T, Akamatsu S, Saito R, Tsuruyama T, Ogawa O, Kobayashi T. Anti-tumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer. Cancer Science. PMID 34212455 DOI: 10.1111/cas.15051  0.17
2012 Inoue T, Tsuchiya N, Matsui S, Kamba T, Mitsuzuka K, Hatakeyama S, Horikawa Y, Ohyama C, Saito S, Arai Y, Ogawa O, Habuchi T. Prediction of survival in patients with metastatic prostate cancer by single nucleotide polymorphisms of cancer-associated genes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 177. PMID 27968102 DOI: 10.1200/jco.2012.30.5_suppl.177  0.169
2021 Kato T, Sugimoto M, Kakehi Y, Shinohara N, Egawa S, Sasaki H, Saito T, Tanikawa T, Matsumura M, Hashine K, Akamatsu S, Ogawa O, Hara I. p2PSA-associated parameters are significant predictors of reclassification of first-year protocol biopsy on active surveillance for early-stage prostate cancer patients: From the PRIAS-JAPAN study. Journal of Clinical Oncology. 39: 153-153. DOI: 10.1200/JCO.2021.39.6_SUPPL.153  0.169
2006 Sato E, Yano I, Jiko M, Takahashi K, Motohashi H, Masuda S, Katsura T, Nishiyama H, Segawa T, Ito N, Kamoto T, Ogawa O, Inui K. Evaluation of Calvert's formula for dosage adjustment of carboplatin in Japanese patients with hormone refractory prostate cancer. Biological & Pharmaceutical Bulletin. 29: 1441-4. PMID 16819185 DOI: JST.JSTAGE/bpb/29.1441  0.169
2019 Akamatsu S, Kubota M, Uozumi R, Narita S, Takahashi M, Mitsuzuka K, Hatakeyama S, Sakurai T, Kawamura S, Ishidoya S, Hoshi S, Ishida M, Mizuno K, Ogura K, Goto T, ... ... Ogawa O, et al. Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer. European Urology Oncology. 2: 320-328. PMID 31200847 DOI: 10.1016/j.euo.2018.10.011  0.169
2006 Kakehi Y, Kamoto T, Shiraishi T, Fukuda H, Saito Y, Kakizoe T, Ogawa O. 1583: PSA-Doubling Time Assessment Based Upon 4 Consecutive Measurements for 6 Months: Is it a Realistic Strategy to Spare Over-Treatment for Patients with Stage T1C Prostate Cancer Presenting Favorable Biopsy Features? Journal of Urology. 175: 510-510. DOI: 10.1016/S0022-5347(18)33775-3  0.169
2008 Matsui Y, Watanabe J, Ikegawa M, Kamoto T, Ogawa O, Nishiyama H. Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3beta with p53. Oncogene. 27: 4603-14. PMID 18391982 DOI: 10.1038/onc.2008.89  0.169
2012 Matsui Y, Assi K, Ogawa O, Raven PA, Dedhar S, Gleave ME, Salh B, So AI. The importance of integrin-linked kinase in the regulation of bladder cancer invasion. International Journal of Cancer. Journal International Du Cancer. 130: 521-31. PMID 21351095 DOI: 10.1002/Ijc.26008  0.169
2002 Kakehi Y, Kamoto T, Shiraishi T, Kato T, Tobisu K, Akakura K, Egawa S, Maeda O, Sumiyoshi Y, Arai Y, Ogawa O. Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men. European Urology. 41: 47-53. PMID 11999465 DOI: 10.1016/S0302-2838(01)00020-3  0.169
2012 Horikawa Y, Tsuchiya N, Matsui S, Kamba T, Narita S, Mitsuzuka K, Hatakeyama S, Inoue T, Saito S, Oyama C, Arai Y, Ogawa O, Habuchi T. 549 Prediction of survival in metastatic prostate cancer patients by single nucleotide polymorphisms of cancer-associated genes European Urology Supplements. 11: e549-e549a. DOI: 10.1016/S1569-9056(12)60546-6  0.169
2016 Kamba T, Kamoto T, Maruo S, Kikuchi T, Shimizu Y, Namiki S, Fujimoto K, Kawanishi H, Sato F, Narita S, Satoh T, Saito H, Sugimoto M, Teishima J, Masumori N, ... ... Ogawa O, et al. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial. International Journal of Clinical Oncology. PMID 27614621 DOI: 10.1007/s10147-016-1037-2  0.168
2015 Kanda S, Tsuchiya N, Narita S, Inoue T, Huang M, Chiba S, Akihama S, Saito M, Numakura K, Tsuruta H, Satoh S, Saito S, Ohyama C, Arai Y, Ogawa O, et al. Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survival. International Journal of Cancer. Journal International Du Cancer. 136: 74-82. PMID 24803183 DOI: 10.1002/ijc.28952  0.168
2022 Kimura H, Mizuno K, Shiota M, Narita S, Terada N, Fujimoto N, Ogura K, Hatano S, Iwasaki Y, Hakozaki N, Ishitoya S, Sumiyoshi T, Goto T, Kobayashi T, Nakagawa H, ... ... Ogawa O, et al. Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer. British Journal of Cancer. PMID 35986085 DOI: 10.1038/s41416-022-01915-2  0.168
2005 Oka H, Chatani Y, Kohno M, Kawakita M, Ogawa O. Constitutive activation of the 41- and 43-kDa mitogen-activated protein (MAP) kinases in the progression of prostate cancer to an androgen-independent state. International Journal of Urology : Official Journal of the Japanese Urological Association. 12: 899-905. PMID 16323984 DOI: 10.1111/j.1442-2042.2005.01164.x  0.168
2010 Ding S, Nishizawa K, Kobayashi T, Oishi S, Lv J, Fujii N, Ogawa O, Nishiyama H. A potent chemotherapeutic strategy for bladder cancer: (S)-methoxy-trityl-L-cystein, a novel Eg5 inhibitor. The Journal of Urology. 184: 1175-81. PMID 20663523 DOI: 10.1016/j.juro.2010.04.073  0.168
2011 Tsuchiya N, Matsui S, Narita S, Inoue T, Numakura K, Horikawa Y, Hatakeyama S, Ohyama C, Arai Y, Saito S, Ogawa O, Habuchi T. 2287 PREDICTION OF SURVIVAL IN METASTATIC PROSTATE CANCER PATIENTS BY SNP ARRAY ANALYSIS OF CANCER-ASSOCIATED GENES Journal of Urology. 185. DOI: 10.1016/j.juro.2011.02.2532  0.167
2012 Kakehi Y, Oka H, Mitsumori K, Itoh N, Ogawa O, Yoshida O. Elevation of serum transforming growth factor-β1 Level in patients with metastatic prostate cancer. Urologic Oncology. 2: 131-5. PMID 21224156 DOI: 10.1016/S1078-1439(96)00078-6  0.167
2016 Kobayashi T, Kamba T, Terada N, Yamasaki T, Inoue T, Ogawa O. High incidence of urological complications in men dying from prostate cancer. International Journal of Clinical Oncology. PMID 27263107 DOI: 10.1007/s10147-016-0993-x  0.167
2004 Inoue T, Segawa T, Yoshida T, Kinoshita H, Kamoto T, Shiraishi T, Srivastava S, Moul JW, Ogawa O. 604: Immunohistochemical Analysis of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Expression in Prostate Cancer Journal of Urology. 171: 160-161. DOI: 10.1016/S0022-5347(18)37866-2  0.166
1999 Iinuma M, Sato K, Ogawa O, Sasaki R, Kato T. [Detection of prostate-specific antigen mRNA in preoperative peripheral blood of patients with prostate cancer: relationship to pathological parameters of the surgical specimens]. Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology. 90: 548-56. PMID 10386054 DOI: 10.5980/JPNJUROL1989.90.548  0.166
2015 Inoue T, Kinoshita H, Terada N, Kobayashi T, Yamasaki T, Matsui Y, Kamba T, Inui H, Sugi M, Matsuda T, Ogawa O. Evaluation of prognostic factors after radical prostatectomy in pT3b prostate cancer patients in Japanese population. Japanese Journal of Clinical Oncology. 45: 780-4. PMID 25981623 DOI: 10.1093/jjco/hyv077  0.166
2014 Ikeda I, Mizowaki T, Norihisa Y, Takayama K, Kamba T, Inoue T, Nakamura E, Kamoto T, Ogawa O, Hiraoka M. Long-term outcomes of dynamic conformal arc irradiation combined with neoadjuvant hormonal therapy in Japanese patients with T1c-T2N0M0 prostate cancer: case series study. Japanese Journal of Clinical Oncology. 44: 180-5. PMID 24379210 DOI: 10.1093/jjco/hyt197  0.165
2016 Kobayashi T, Kimura T, Lee C, Inoue T, Terada N, Kono Y, Kamba T, Kim CS, Egawa S, Ogawa O. Subclassification of high-risk clinically organ-confined prostate cancer for early cancer-specific mortality after radical prostatectomy. Japanese Journal of Clinical Oncology. PMID 27207889 DOI: 10.1093/jjco/hyw061  0.165
2016 Akamatsu S, Wyatt A, Lin D, Lysakowski S, Zhang F, Kawai Y, Fazli L, Ogawa O, Lotan T, Rubin M, Beltran H, Zoubeidi A, Wang Y, Gleave M, Collins C. 138 Exploring a novel therapeutic target for neuroendocrine prostate cancer using a xenograft model of trans-differentiation European Urology Supplements. 15: e138. DOI: 10.1016/S1569-9056(16)60140-9  0.165
2018 Iguchi T, Takaori K, Mii A, Sato Y, Suzuki Y, Yoshifuji H, Seno H, Ogawa O, Omori K, Bessho K, Kondo S, Yoshizaki T, Nakashima H, Saito T, Mimori T, et al. Glucocorticoid receptor expression in resident and hematopoietic cells in IgG4-related disease. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 29434340 DOI: 10.1038/s41379-018-0036-4  0.164
1998 Yoshimura N, Takami N, Ogawa O, Kakehi Y, Okada Y, Fukui T, Yoshida O. Decision analysis for treatment of early stage prostate cancer. Japanese Journal of Cancer Research : Gann. 89: 681-9. PMID 9703367 DOI: 10.1111/j.1349-7006.1998.tb03271.x  0.164
2023 Ogata T, Aizawa R, Nakamura K, Kobayashi T, Akamatsu S, Nakamura E, Ogawa O, Mizowaki T. Impact of Long-term Adjuvant Hormonal Therapy in High-dose IMRT for Unfavorable Locally Advanced Prostate Cancer. Anticancer Research. 43: 3589-3596. PMID 37500135 DOI: 10.21873/anticanres.16538  0.164
2006 Ito M, Nishiyama H, Watanabe J, Kawanishi H, Takahashi T, Kamoto T, Habuchi T, Ogawa O. Association of the PIG3 promoter polymorphism with invasive bladder cancer in a Japanese population. Japanese Journal of Clinical Oncology. 36: 116-20. PMID 16418181 DOI: 10.1093/jjco/hyi225  0.164
2020 Shiota* M, Akamatsu S, Narita S, Sumiyoshi T, Fujiwara M, Uchiumi T, Ogawa O, Habuchi T, Eto M. MP09-18 MISSENSE POLYMORPHISM IN SRD5A2 IN COMBINATION WITH HSD3B1 VARIATION IS ASSOCIATED WITH OUTCOME OF CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ABIRATERONE The Journal of Urology. 203: e122. DOI: 10.1097/JU.0000000000000829.018  0.164
2008 Sakamoto M, Mizowaki T, Mitsumori M, Takayama K, Sasai K, Negoro Y, Norihisa Y, Kamoto T, Ogawa O, Hiraoka M. Is Adjuvant Hormonal Therapy Necessary to Japanese Patients with Locally Advanced Prostate Cancer Treated by 3D-CRT? International Journal of Radiation Oncology*Biology*Physics. 72: S339. DOI: 10.1016/J.IJROBP.2008.06.1143  0.164
2005 Segawa T, Kamoto T, Kinoshita H, Kunishima Y, Yoshimura K, Ito A, Takahashi T, Higashi S, Nakamura E, Nishiyama H, Ito N, Yamamoto S, Habuchi T, Ogawa O. Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer. International Journal of Clinical Oncology. 10: 333-7. PMID 16247660 DOI: 10.1007/s10147-005-0513-x  0.164
2015 Kamba T, Kamoto T, Shimizu Y, Namiki S, Fujimoto K, Kawanishi H, Sato F, Narita S, Satoh T, Saito H, Sugimoto M, Teishima J, Egawa S, Sakai H, Okada Y, ... ... Ogawa O, et al. 669 A phase III, multicenter, randomized, controlled study of maximum androgen blockade with vs without zoledronic acid in prostate cancer patients with metastatic bone disease: Results of main secondary endpoints in ZAPCA trial European Urology Supplements. 14: e669. DOI: 10.1016/S1569-9056(15)60662-5  0.163
1996 Okuno H, Kakehi Y, Ogawa O, Yamada H, Ozdemir E, Okada Y, Yoshida O. Immunocytochemical detection of p53 in cultures of exfoliated cells from urine of patients with urothelial cancers. Japanese Journal of Cancer Research : Gann. 87: 718-23. PMID 8698621 DOI: 10.1111/j.1349-7006.1996.tb00283.x  0.163
2013 Tsuchiya N, Narita S, Inoue T, Saito M, Numakura K, Huang M, Hatakeyama S, Satoh S, Saito S, Ohyama C, Arai Y, Ogawa O, Habuchi T. Insulin-like growth factor-1 genotypes and haplotypes influence the survival of prostate cancer patients with bone metastasis at initial diagnosis. Bmc Cancer. 13: 150. PMID 23530598 DOI: 10.1186/1471-2407-13-150  0.163
2013 Akaza H, Hinotsu S, Usami M, Ogawa O, Kitamura T, Suzuki K, Tsukamoto T, Naito S, Namiki M, Hirao Y, Murai M. Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score. Prostate International. 1: 81-8. PMID 24223407 DOI: 10.12954/PI.12016  0.163
2023 Murakami K, Furuya H, Hokutan K, Goodison S, Pagano I, Chen R, Shen CH, Chan MWY, Ng CF, Kobayashi T, Ogawa O, Miyake M, Thornquist M, Shimizu Y, Hayashi K, et al. Association of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome in Bladder Cancer. International Journal of Molecular Sciences. 24. PMID 36902377 DOI: 10.3390/ijms24054943  0.162
2019 Shiota M, Narita S, Akamatsu S, Fujimoto N, Sumiyoshi T, Fujiwara M, Uchiumi T, Habuchi T, Ogawa O, Eto M. Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone. Jama Network Open. 2: e190115. PMID 30794306 DOI: 10.1001/jamanetworkopen.2019.0115  0.162
2017 Ito K, Kobayashi T, Furuta A, Teramoto Y, Terada N, Akamatsu S, Yamasaki T, Inoue T, Ogawa O. MP20-08 PROSTATE CANCER LOCI WITH NEGATIVE MULTIPARAMETRIC MRI FOR PROSTATE CANCER: CORRELATION WITH PROSTATECTOMY SPECIMENS Journal of Urology. 197. DOI: 10.1016/j.juro.2017.02.640  0.162
2009 Terada N, Shimizu Y, Kamba T, Maeno A, Kobayashi T, Inoue T, Nakamura E, Kamoto T, Tsujimoto G, Ogawa O. MP-15.03: EP4 Is a Novel Potential Target for the Treatment of Androgen-Independent Prostate Cancer Urology. 74: S114-S115. DOI: 10.1016/J.UROLOGY.2009.07.837  0.162
2010 Ma Z, Tsuchiya N, Yuasa T, Huang M, Obara T, Narita S, Horikawa Y, Tsuruta H, Saito M, Satoh S, Ogawa O, Habuchi T. Clinical significance of polymorphism and expression of chromogranin a and endothelin-1 in prostate cancer. The Journal of Urology. 184: 1182-8. PMID 20663522 DOI: 10.1016/j.juro.2010.04.063  0.161
2014 Sakatani T, Shimizu Y, Sugino Y, Yamasaki T, Imamura M, Matsui Y, Inoue T, Okubo K, Kamba T, Yoshimura K, Ogawa O. [Small cell carcinoma of the bladder]. Hinyokika Kiyo. Acta Urologica Japonica. 60: 221-5. PMID 24894857  0.161
2017 Terada N, Maughan BL, Akamatsu S, Kobayashi T, Yamasaki T, Inoue T, Kamba T, Ogawa O, Antonarakis ES. Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 28455853 DOI: 10.1111/iju.13346  0.161
2016 Akaza H, Hirao Y, Kim CS, Oya M, Ozono S, Ye D, Cooperberg M, Hinotsu S, Lee JY, Zhu G, Namiki M, Horie S, Chung BH, Chen CH, Fai NC, ... ... Ogawa O, et al. Asia prostate cancer study (A-CaP Study) launch symposium Prostate International. DOI: 10.1016/j.prnil.2016.03.001  0.161
2016 Akaza H, Hirao Y, Kim CS, Oya M, Ozono S, Ye D, Cooperberg M, Hinotsu S, Lee JY, Zhu G, Namiki M, Horie S, Chung BH, Chen CH, Fai NC, ... ... Ogawa O, et al. Asia prostate cancer study (A-CaP Study) launch symposium. Prostate International. 4: 88-96. PMID 27689065 DOI: 10.1016/J.Prnil.2016.03.001  0.161
2013 Kinoshita H, Shimizu Y, Mizowaki T, Takayama K, Norihisa Y, Kamoto T, Kamba T, Hayashino Y, Hiraoka M, Ogawa O. Risk factors predicting the outcome of salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy. International Journal of Urology : Official Journal of the Japanese Urological Association. 20: 806-11. PMID 23293977 DOI: 10.1111/iju.12049  0.161
2016 Mizuno K, Inoue T, Kinoshita H, Yano T, Kawanishi H, Kanda H, Terada N, Kobayashi T, Kamba T, Mikami Y, Shiraishi T, Uemura Y, Imai Y, Honjo G, Shirase T, ... ... Ogawa O, et al. Evaluation of predictors of unfavorable pathological features in men eligible for active surveillance using radical prostatectomy specimens: a multi-institutional study. Japanese Journal of Clinical Oncology. PMID 27744325 DOI: 10.1093/jjco/hyw130  0.161
2014 Miyazaki Y, Nakayama K, Sekiya S, Inoue T, Goto T, Terada N, Kajihara S, Kawabata S, Iwamoto S, Tanaka K, Ogawa O. 202 Discovery of urinary biomarker candidates for prostate cancer based on proteomic analyses European Urology Supplements. 13: e202-e202a. DOI: 10.1016/S1569-9056(14)60199-8  0.161
2010 Takata R, Akamatsu S, Kubo M, Takahashi A, Hosono N, Kawaguchi T, Tsunoda T, Inazawa J, Kamatani N, Ogawa O, Fujioka T, Nakamura Y, Nakagawa H. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nature Genetics. 42: 751-4. PMID 20676098 DOI: 10.1038/ng.635  0.161
2012 Akao T, Kakehi Y, Wu XX, Kinoshita H, Takahashi T, Ogawa O, Kato T, Yoshida O. Semi-quantitative analysis of telomerase activity of exfoliated cells in urine of patients with urothelial cancers: Causative factors affecting sensitivity and specificity. Urologic Oncology. 3: 118-24. PMID 21227116 DOI: 10.1016/S1078-1439(98)00009-X  0.161
2016 Terada N, Akamatsu S, Okada Y, Negoro H, Kobayashi T, Yamasaki T, Matsui Y, Inoue T, Kamba T, Ogawa O. Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study. International Journal of Clinical Oncology. PMID 27351872 DOI: 10.1007/s10147-016-1004-y  0.16
2013 Nishimura K, Nonomura N, Hashine K, Kanayama HO, Ozono S, Miura T, Miki T, Kakehi Y, Arai Y, Ogawa O, Fujita R, Nonomura K, Mizokami A, Hoshi S, Akaza H. Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan. International Journal of Clinical Oncology. 18: 306-13. PMID 22350099 DOI: 10.1007/S10147-012-0380-1  0.16
2014 Goto T, Terada N, Inoue T, Nakayama K, Okada Y, Yoshikawa T, Miyazaki Y, Uegaki M, Sumiyoshi S, Kobayashi T, Kamba T, Yoshimura K, Ogawa O. The expression profile of phosphatidylinositol in high spatial resolution imaging mass spectrometry as a potential biomarker for prostate cancer. Plos One. 9: e90242. PMID 24587297 DOI: 10.1371/journal.pone.0090242  0.159
2012 Kato K, Inoue T, Yamazaki T, Matsui Y, Shimizu Y, Kamba H, Yoshimura K, Ogawa O, Ikeda I, Norihisa Y, Ogura M, Mizowaki T, Hiraoka M. 511 INCIDENCE OF BLADDER CANCER AFTER CURATIVE RADIATION THERAPY VERSUS RADICAL PROSTATECTOMY FOR LOCALIZED PROSTATE CANCER Journal of Urology. 187. DOI: 10.1016/J.JURO.2012.02.582  0.159
2008 Terada N, Shimizu Y, Yoshida T, Kobayashi T, Kamba T, Segawa T, Nakamura E, Kamoto T, Ogawa O. MECHANISMS OF ACQUIRING ANDROGEN-INDEPENDENCE IN NOVEL PROSTATE CANCER XENOGRAFT MODEL European Urology Supplements. 7: 310. DOI: 10.1016/S1569-9056(08)60952-5  0.159
2000 Takahashi T, Habuchi T, Kakehi Y, Okuno H, Terachi T, Kato T, Ogawa O. Molecular diagnosis of metastatic origin in a patient with metachronous multiple cancers of the renal pelvis and bladder. Urology. 56: 331. PMID 10925115 DOI: 10.1016/S0090-4295(00)00574-4  0.158
2010 Nishizawa K, Nishiyama H, Oishi S, Tanahara N, Kotani H, Mikami Y, Toda Y, Evans BJ, Peiper SC, Saito R, Watanabe J, Fujii N, Ogawa O. Fluorescent imaging of high-grade bladder cancer using a specific antagonist for chemokine receptor CXCR4. International Journal of Cancer. Journal International Du Cancer. 127: 1180-7. PMID 20039317 DOI: 10.1002/Ijc.25145  0.158
2001 Mizutani Y, Nakao M, Ogawa O, Yoshida O, Bonavida B, Miki T. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. The Journal of Urology. 165: 263-70. PMID 11125422 DOI: 10.1097/00005392-200101000-00076  0.158
2011 Ogawa O. [History and present status of the treatment of prostate cancer]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 69: 326-9. PMID 22207995  0.158
2016 Akaza H, Uemura H, Tsukamoto T, Ozono S, Ogawa O, Sakai H, Oya M, Namiki M, Fukasawa S, Yamaguchi A, Uemura H, Ohashi Y, Maeda H, Saito A, Takeda K, et al. A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer. International Journal of Clinical Oncology. PMID 26793974 DOI: 10.1007/s10147-016-0952-6  0.158
2019 Mizowaki T, Takayama K, Nakamura K, Aizawa R, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Ogawa O. Outcomes of high-dose whole pelvic simultaneous integrated boost IMRT in patients with pelvic lymph node-positive prostate cancer. Journal of Clinical Oncology. 37: 192-192. DOI: 10.1200/JCO.2019.37.7_SUPPL.192  0.158
2008 Awakura Y, Nakamura E, Ito N, Kamoto T, Ogawa O. Methylation-associated silencing of TU3A in human cancers. International Journal of Oncology. 33: 893-9. PMID 18813805  0.158
2014 Okada Y, Kakizaki F, Uegaki M, Goto T, Yoshikawa T, Terada N, Kobayashi T, Inoue T, Ogawa O, Taketo M. MP41-08 AMINO-TERMINAL ENHANCER OF SPLIT/ AES IS A TUMOR AND METASTASIS SUPPRESSOR OF PROSTATE CANCER Journal of Urology. 191. DOI: 10.1016/J.JURO.2014.02.1225  0.158
2018 Onozawa M, Akaza H, Hinotsu S, Oya M, Ogawa O, Kitamura T, Suzuki K, Naito S, Namiki M, Nishimura K, Hirao Y, Tsukamoto T. Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching. Cancer Medicine. PMID 30151999 DOI: 10.1002/Cam4.1735  0.158
2006 Kamoto T, Mizowaki T, Mitsumori M, Hiraoka M, Kobayashi T, Shimizu Y, Inoue T, Segawa T, Nakamura E, Ogawa O. COMPARATIVE ANALYSIS OF POST-TREATMENT BIOCHEMICAL OUTCOMES OF LOCALISED PROSTATE CANCER IN A JAPANESE POPULATION: WHAT IS THE BEST APPROACH FOR HIGH-RISK PATIENTS? European Urology Supplements. 5: 203. DOI: 10.1016/S1569-9056(06)60728-8  0.158
2017 Nakamura K, Mizowaki T, Inokuchi H, Ikeda I, Inoue T, Kamba T, Ogawa O, Hiraoka M. Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance. International Journal of Clinical Oncology. PMID 28756594 DOI: 10.1007/s10147-017-1174-2  0.158
2015 Okada Y, Kobayashi T, Makino Y, Uegaki M, Miyazaki Y, Goto T, Yoshikawa T, Terada N, Inoue T, Kamba T, Ogawa O, Taketo M. 287 Amino-terminal enhancer of split/AES is a tumor and metastasis suppressor of prostate cancer European Urology Supplements. 14: e287-e287a. DOI: 10.1016/S1569-9056(15)60284-6  0.158
2006 Mitsumori M, Sasaki Y, Mizowaki T, Takayama K, Nagata Y, Hiraoka M, Negoro Y, Sasai K, Kinoshita H, Kamoto T, Ogawa O. Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure. International Journal of Clinical Oncology. 11: 396-402. PMID 17058138 DOI: 10.1007/s10147-006-0600-7  0.157
2019 Kobayashi T, Terada N, Kimura T, Matsubara N, Murakami K, Mori K, Fujimoto Y, Akamatsu S, Inoue T, Ogawa O. Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up. Clinical Genitourinary Cancer. PMID 31759831 DOI: 10.1016/j.clgc.2019.09.011  0.157
2013 Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S. Importance of performance status, corrected calcium, and microvascular invasion in predicting overall survival in patients with metastatic renal cell carcinoma at the era of molecular targeted therapy. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E15588  0.157
2021 Li X, Nakayama K, Goto T, Kimura H, Akamatsu S, Hayashi Y, Fujita K, Kobayashi T, Shimizu K, Nonomura N, Ogawa O, Inoue T. High Level of Phosphatidylcholines/Lysophosphatidylcholine Ratio in Urine is Associated with Prostate Cancer. Cancer Science. PMID 34328656 DOI: 10.1111/cas.15093  0.157
2006 Inoue T, Segawa T, Shiraishi T, Yamada T, Kinukawa N, Yoshida T, Toda Y, Shimizu Y, Nakamura E, Kinoshita H, Kamoto T, Ogawa O. High-grade and hormone-treated prostate cancer express high levels of thymidylate synthase. Bju International. 98: 197-200. PMID 16831168 DOI: 10.1111/j.1464-410X.2006.06219.x  0.157
2020 Kita Y, Saito R, Inoue T, Kim WY, Ogawa O, Kobayashi T. Patient-Derived Urothelial Cancer Xenograft Models: A Systematic Review and Future Perspectives Bladder Cancer. 6: 131-141. DOI: 10.3233/blc-200281  0.157
2003 Kakehi Y, Kamoto T, Ogawa O, Arai Y, Litwin MS, Suzukamo Y, Fukuhara S. Development of Japanese version of the UCLA Prostate Cancer Index: a pilot validation study. International Journal of Clinical Oncology. 7: 306-11. PMID 12402065 DOI: 10.1007/s101470200045  0.157
2022 Haitani T, Kobayashi M, Koyasu S, Akamatsu S, Suwa T, Onodera Y, Nam JM, Nguyen PTL, Menju T, Date H, Ogawa O, Harada H. Proteolysis of a histone acetyl reader, ATAD2, induces chemoresistance of cancer cells under severe hypoxia by inhibiting cell cycle progression in S phase. Cancer Letters. 528: 76-84. PMID 34973392 DOI: 10.1016/j.canlet.2021.12.028  0.157
2021 Inoue T, Yoshimura K, Terada N, Tsukino H, Murota T, Kinoshita H, Kamoto T, Ogawa O, Matsuda T. Prostate-specific antigen density during dutasteride treatment for 1 year predicts the presence of prostate cancer in benign prostatic hyperplasia after the first negative biopsy (PREDICT study). International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 34008275 DOI: 10.1111/iju.14590  0.157
2021 Aizawa R, Takayama K, Nakamura K, Ogata T, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Tashiro Y, Ota H, Ogawa O, Mizowaki T. Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: A combination of prostate-targeted treatment and metastasis-directed therapy. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 33811409 DOI: 10.1111/iju.14567  0.156
2007 Kakehi Y, Takegami M, Suzukamo Y, Namiki S, Arai Y, Kamoto T, Ogawa O, Fukuhara S. Health related quality of life in Japanese men with localized prostate cancer treated with current multiple modalities assessed by a newly developed Japanese version of the Expanded Prostate Cancer Index Composite. The Journal of Urology. 177: 1856-61. PMID 17437836 DOI: 10.1016/j.juro.2007.01.066  0.156
2008 Kakehi Y, Kamoto T, Shiraishi T, Ogawa O, Suzukamo Y, Fukuhara S, Saito Y, Tobisu K, Kakizoe T, Shibata T, Fukuda H, Akakura K, Suzuki H, Shinohara N, Egawa S, et al. Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Japanese Journal of Clinical Oncology. 38: 122-8. PMID 18272471 DOI: 10.1093/jjco/hym161  0.156
2013 Tsuchiya N, Matsui S, Narita S, Kamba T, Mitsuzuka K, Hatakeyama S, Horikawa Y, Inoue T, Saito S, Ohyama C, Arai Y, Ogawa O, Habuchi T. Distinct cancer-specific survival in metastatic prostate cancer patients classified by a panel of single nucleotide polymorphisms of cancer-associated genes. Genes & Cancer. 4: 54-60. PMID 23946871 DOI: 10.1177/1947601913481354  0.156
2020 Nagai* T, Terada N, Mukai S, Fujii M, Takamori H, Okasyo K, Akamatsu S, Ogawa O, Kamoto T. MP09-16 IDENTIFICATION OF IL13RA2 AS A BIOMARKER FOR PREDICTING CASTRATION-RESISTANCE OF PROSTATE CANCER USING PATIENT DERIVED XENOGRAFT MODELS The Journal of Urology. 203: e121-e122. DOI: 10.1097/JU.0000000000000829.016  0.156
2009 Sengiku A, Nishiyama H, Shimizu T, Watanabe J, Soda T, Kamba T, Yoshimura K, Kanematsu A, Nakamura E, Kamoto T, Ogawa O. [A case report: recurrence of urothelial cancer in an ileal conduit]. Hinyokika Kiyo. Acta Urologica Japonica. 55: 345-8. PMID 19588868  0.155
2003 Akaza H, Chang SJ, Chen KK, Esuvaranathan K, Fujioka T, Hirao Y, Hong SJ, Hinotsu S, Kim WJ, Lau W, Lee SE, Murai M, Naito S, Ogawa O, Rim JS, et al. The 2nd conference on Asian trends in prostate cancer hormone therapy. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 30: 1533-42. PMID 14584292  0.155
2003 Li Z, Habuchi T, Mitsumori K, Kamoto T, Kinoshitu H, Segawa T, Ogawa O, Kato T. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. The Journal of Urology. 169: 2378-81. PMID 12771801 DOI: 10.1097/01.JU.0000056152.57018.31  0.155
2011 Nishizawa K, Nishiyama H, Matsui Y, Kobayashi T, Saito R, Kotani H, Masutani H, Oishi S, Toda Y, Fujii N, Yodoi J, Ogawa O. Thioredoxin-interacting protein suppresses bladder carcinogenesis. Carcinogenesis. 32: 1459-66. PMID 21771725 DOI: 10.1093/carcin/bgr137  0.155
2017 Ito K, Negoro H, Kubota M, Takada H, Magaribuchi T, Sawada A, Akamatsu S, Kobayashi T, Terada N, Yamasaki T, Inoue T, Kamba T, Teramoto Y, Ogawa O. [A Case of Thyroid-Like Follicular Carcinoma of the Kidney]. Hinyokika Kiyo. Acta Urologica Japonica. 63: 145-149. PMID 28506051  0.155
2015 Schmitz-Dräger BJ, Droller M, Lokeshwar VB, Lotan Y, Hudson MA, van Rhijn BW, Marberger MJ, Fradet Y, Hemstreet GP, Malmstrom PU, Ogawa O, Karakiewicz PI, Shariat SF. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urologia Internationalis. 94: 1-24. PMID 25501325 DOI: 10.1159/000369357  0.155
2007 Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Namiki M, Hirao Y, Murai M, Yamanaka H. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Japanese Journal of Clinical Oncology. 37: 775-81. PMID 17965423 DOI: 10.1093/jjco/hym098  0.154
2006 Yokomizo A, Murai M, Baba S, Ogawa O, Tsukamoto T, Niwakawa M, Tobisu K, Kinukawa N, Naito S. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan. Bju International. 98: 549-53. PMID 16925752 DOI: 10.1111/j.1464-410X.2006.06379.x  0.154
2008 Nishiyama H, Watanabe J, Ogawa O. p53 and chemosensitivity in bladder cancer. International Journal of Clinical Oncology. 13: 282-6. PMID 18704627 DOI: 10.1007/s10147-008-0815-x  0.154
2010 Terada N, Shimizu Y, Yoshida T, Maeno A, Kamba T, Inoue T, Nakamura E, Kamoto T, Ogawa O. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft. The Prostate. 70: 252-61. PMID 19790238 DOI: 10.1002/pros.21058  0.154
2007 Kageyama S, Iwaki H, Inoue H, Isono T, Yuasa T, Nogawa M, Maekawa T, Ueda M, Kajita Y, Ogawa O, Toguchida J, Yoshiki T. A novel tumor-related protein, C7orf24, identified by proteome differential display of bladder urothelial carcinoma. Proteomics. Clinical Applications. 1: 192-9. PMID 21136669 DOI: 10.1002/prca.200600468  0.154
2010 Yoshimura K, Kamoto T, Ogawa O, Matsui S, Tsuchiya N, Tada H, Murata K, Yoshimura K, Habuchi T, Fukushima M. Medical mushrooms used for biochemical failure after radical treatment for prostate cancer: an open-label study. International Journal of Urology : Official Journal of the Japanese Urological Association. 17: 548-54. PMID 20412340 DOI: 10.1111/j.1442-2042.2010.02528.x  0.154
2006 Kakehi Y, Kamoto T, Ogawa O, Tobisu K, Saito Y, Fukuda H, Kakizoe T. Prospective evaluation of a “Watchful Waiting” program using initial pathology criteria and PSA-doubling time monitoring for patients with stage T1c prostate cancer Journal of Clinical Oncology. 24: 14651-14651. DOI: 10.1200/JCO.2006.24.18_SUPPL.14651  0.154
2017 Ito K, Kobayashi T, Koyama T, Tsuzuki T, Kamoto T, Okada Y, Inoue T, Ogawa O. Left renal mass presenting uncommon pattern of extension in a patient with intestinal malrotation. International Cancer Conference Journal. 6: 88-91. PMID 31149478 DOI: 10.1007/s13691-017-0282-1  0.154
2021 Uemura H, Kobayashi K, Yokomizo A, Hinotsu S, Horie S, Kakehi Y, Naito S, Nonomura N, Ogawa O, Oya M, Suzuki K, Saito A, Uno S, Akaza H. Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration-resistant prostate cancer: AFTERCAB study. Bjui Compass. 3: 26-36. PMID 35475157 DOI: 10.1002/bco2.103  0.153
2004 Akaza H, Usami M, Hinotsu S, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Hirao Y, Murai M, Yamanaka H. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Japanese Journal of Clinical Oncology. 34: 329-36. PMID 15333685 DOI: 10.1093/JJCO/HYH061  0.153
2022 Sekine Y, Iwasaki Y, Aoi T, Endo M, Hirata M, Kamatani Y, Matsuda K, Sugano K, Yoshida T, Murakami Y, Fukui T, Akamatsu S, Ogawa O, Nakagawa H, Numakura K, et al. Different risk genes contribute to clear cell and non-clear cell renal cell carcinoma in 1532 Japanese patients and 5996 controls. Human Molecular Genetics. 31: 1962-1969. PMID 35764097 DOI: 10.1093/hmg/ddab345  0.153
2022 Hagimoto H, Sano T, Kashima S, Yoshino T, Goto T, Sawada A, Akamatsu S, Yamasaki T, Fujimoto M, Kajita Y, Kobayashi T, Ogawa O. Rapidly Progressive Bladder Cancer Diagnosed because of Spontaneous Bladder Rupture. Case Reports in Urology. 2022: 4586199. PMID 35585958 DOI: 10.1155/2022/4586199  0.152
2002 Suzukamo Y, Kakehi Y, Kamoto T, Arai Y, Ogawa O, Fukuhara S. [Translation and adaptation of the UCLA prostate cancer index for use in Japan]. Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology. 93: 659-68. PMID 12385090 DOI: 10.5980/jpnjurol1989.93.659  0.152
2000 Kakehi Y, Kamoto T, Ogawa O, Kato T, Tobisu K, Akakura K, Egawa S, Usami M, Maeda O, Arai Y, Sumiyoshi Y, Kamiryo Y, Yoshida O. Clinical significance of nonpalpable prostate cancer with favorable biopsy features in Japanese men. European Urology. 37: 552-8. PMID 10765093 DOI: 10.1159/000020192  0.152
2012 Inoue T, Segawa T, Maeno A, Akamatsu S, Yoshikawa T, Shimizu Y, Tomomi K, Yoshimura K, Dobi A, Srivastava S, Ogawa O. 329 ERG ONCOPROTEIN EXPRESSION IN LOCALIZED PROSTATE CANCER IN JAPANESE POPULATION Journal of Urology. 187. DOI: 10.1016/J.JURO.2012.02.389  0.152
2013 Matsuoka T, Sugino Y, Kobayashi T, Terada N, Yamasaki T, Matsui Y, Imamura M, Okubo K, Kamba T, Yoshimura K, Ogawa O. [A case of prostate carcinosarcoma successfully treated with combined modality therapy]. Hinyokika Kiyo. Acta Urologica Japonica. 59: 749-52. PMID 24322415  0.152
2009 Tsuchiya N, Narita S, Kumazawa T, Inoue T, Ma Z, Tsuruta H, Saito M, Horikawa Y, Yuasa T, Satoh S, Ogawa O, Habuchi T. Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer. Oncology Reports. 22: 493-9. PMID 19639194 DOI: 10.3892/or_00000462  0.152
2013 Goto T, Terada N, Inoue T, Yoshikawa T, Kobayashi T, Shimizu Y, Kamba T, Yoshimura K, Nishi E, Ogawa O. 204 NARDILYSIN IS ASSOCIATED WITH PROSTATE CANCER AGGRESSIVENESS AND IS A POTENTIAL TISSUE AND SERUM MARKER Journal of Urology. 189. DOI: 10.1016/J.JURO.2013.02.1584  0.152
2005 Tsuchiya N, Lizhong W, Fukuda H, Suzuki H, Shinbo M, Segawa T, Kamoto T, Mitsumori K, Ichikawa T, Ogawa O, Kato T, Habuchi T. 255: Prognostic Prediction of Metastatic Prostate Cancer Using Genetic Polymorphisms Journal of Urology. 173: 70-70. DOI: 10.1016/S0022-5347(18)34520-8  0.151
2022 Aizawa R, Tsuzuki T, Haga H, Nakamura K, Ogata T, Inoue T, Kobayashi T, Akamatsu S, Goto T, Ogawa O, Mizowaki T. Clinical significance of IDC-P as predictive factor after intensity-modulated radiation therapy. Cancer Science. PMID 35514196 DOI: 10.1111/cas.15392  0.151
2019 Ogawa O, Suzuki T, Habuchi T, Sasaki R, Tachiki Y, Akao T, Tsuchiya N, Kato T. Association of vitamin D receptor gene polymorphism with protection against prostate cancer and benign prostate hyperplasia. Prostate Cancer and Prostatic Diseases. 2: S24. PMID 12496803 DOI: 10.1038/sj.pcan.4500349  0.151
2009 Soda T, Okubo K, Ichioka K, Okuno H, Kohama N, Nakayama T, Hatayama H, Nishiyama H, Ogawa O. [Sperm cryopreservation for cancer patients: 5-year experience in a private hospital in Japan]. Hinyokika Kiyo. Acta Urologica Japonica. 55: 9-13. PMID 19227205  0.151
2020 Mizuno* K, Akamatsu S, Sumiyoshi T, Goto T, Kobayashi T, Yamasaki T, Inoue T, Fujimoto A, Ogawa O. MP16-17 GENOMIC LANDSCAPE OF METASTATIC HORMONE- NAÏVE PROSTATE CANCER Journal of Urology. 203. DOI: 10.1097/JU.0000000000000841.017  0.151
2015 Ito N, Kojima S, Teramukai S, Mikami Y, Ogawa O, Kamba T. Outcomes of curative nephrectomy against renal cell carcinoma based on a central pathological review of 914 specimens from the era of cytokine treatment. International Journal of Clinical Oncology. PMID 25981949 DOI: 10.1007/s10147-015-0840-5  0.151
2008 Awakura Y, Nakamura E, Takahashi T, Kotani H, Mikami Y, Kadowaki T, Myoumoto A, Akiyama H, Ito N, Kamoto T, Manabe T, Nobumasa H, Tsujimoto G, Ogawa O. Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma. Journal of Cancer Research and Clinical Oncology. 134: 1363-9. PMID 18483744 DOI: 10.1007/s00432-008-0412-4  0.151
2006 Kawahara T, Nishiyama H, Yamamoto S, Kamoto T, Ogawa O. Protocol consisting of cisplatin, etoposide and irinotecan induced complete pathological remission of primary small cell carcinoma of the bladder. International Journal of Urology : Official Journal of the Japanese Urological Association. 13: 1251-3. PMID 16984565 DOI: 10.1111/j.1442-2042.2006.01521.x  0.151
2007 Sawai K, Mukoyama M, Mori K, Kasahara M, Koshikawa M, Yokoi H, Yoshioka T, Ogawa Y, Sugawara A, Nishiyama H, Yamada S, Kuwahara T, Saleem MA, Shiota K, Ogawa O, et al. Expression of CCN1 (CYR61) in developing, normal, and diseased human kidney. American Journal of Physiology. Renal Physiology. 293: F1363-72. PMID 17699553 DOI: 10.1152/ajprenal.00205.2007  0.15
2016 Goodison S, Ogawa O, Matsui Y, Kobayashi T, Miyake M, Ohnishi S, Fujimoto K, Dai Y, Shimizu Y, Tsukikawa K, Furuya H, Rosser CJ. A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort. Journal of Translational Medicine. 14: 287. PMID 27717367 DOI: 10.1186/s12967-016-1043-1  0.15
2013 Ueda K, Tatsuguchi A, Saichi N, Toyama A, Tamura K, Furihata M, Takata R, Akamatsu S, Igarashi M, Nakayama M, Sato TA, Ogawa O, Fujioka T, Shuin T, Nakamura Y, et al. Plasma low-molecular-weight proteome profiling identified neuropeptide-Y as a prostate cancer biomarker polypeptide. Journal of Proteome Research. 12: 4497-506. PMID 23991666 DOI: 10.1021/pr400547s  0.15
2003 Kinoshita H, Habuchi T, Ogawa O. [Molecular and endocrinological mechanism of benign prostatic hyperplasia and prostate cancer]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 23-7. PMID 12599539  0.15
2009 Kajita Y, Furu M, Nagayama S, Nishiyama H, Nakamura E, Ogawa O, Toguchida J. MP-15.09: Functional Analysis of a Novel Soft Tissue Sarcoma Metastasis-Associated Molecule in Prostate Cancer Urology. 74: S116-S117. DOI: 10.1016/J.UROLOGY.2009.07.843  0.15
2006 Inoue T, Ito T, Narita S, Horikawa Y, Tsuchiya N, Kakinuma H, Mishina M, Nakamura E, Kato T, Ogawa O, Habuchi T. Association of BCL10 germ line polymorphisms on chromosome 1p with advanced stage testicular germ cell tumor patients. Cancer Letters. 240: 41-7. PMID 16229939 DOI: 10.1016/j.canlet.2005.08.019  0.15
2015 Goto T, Terada N, Inoue T, Kobayashi T, Nakayama K, Okada Y, Yoshikawa T, Miyazaki Y, Uegaki M, Utsunomiya N, Makino Y, Sumiyoshi S, Yamasaki T, Kamba T, Ogawa O. Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer. The Prostate. PMID 26332786 DOI: 10.1002/pros.23088  0.15
2019 Terada N, Kamoto T, Tsukino H, Mukai S, Akamatsu S, Inoue T, Ogawa O, Narita S, Habuchi T, Yamashita S, Mitsuzuka K, Arai Y, Kandori S, Kojima T, Nishiyama H, et al. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients. Bmc Cancer. 19: 156. PMID 30770773 DOI: 10.1186/s12885-019-5342-9  0.15
2005 Yoshida T, Segawa T, Inoue T, Shimizu Y, Kamoto T, Shiraishi T, Srivastava S, Maul JW, Ogawa O. 395: Expression Analysis of NDRG1, An Androgen-Induced, Stress Responsive Gene, in Prostate Cancer Journal of Urology. 173: 108-108. DOI: 10.1016/s0022-5347(18)34648-2  0.15
2011 Kinoshita H, Kawa G, Matsuda T, Ogawa O. [Significance of PSA nadir as a tool of predicting biochemical failure after radical prostatectomy for prostate cancer]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 69: 395-8. PMID 22208009  0.149
2020 Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, et al. Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 32172529 DOI: 10.1111/iju.14210  0.149
2012 Mizowaki T, Norihisa Y, Ogura M, Takayama K, Kamba T, Inoue T, Shimizu Y, Kamoto T, Ogawa O, Hiraoka M. Interim Outcomes of a High-dose Whole Pelvic IMRT for Very High-risk Group of Patients With Locally Advanced Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 84: S360. DOI: 10.1016/J.IJROBP.2012.07.951  0.149
2012 Akamatsu S, Takahashi A, Takata R, Kubo M, Inoue T, Morizono T, Tsunoda T, Kamatani N, Haiman CA, Wan P, Chen GK, Le Marchand L, Kolonel LN, Henderson BE, Fujioka T, ... ... Ogawa O, et al. Reproducibility, performance, and clinical utility of a genetic risk prediction model for prostate cancer in Japanese. Plos One. 7: e46454. PMID 23071574 DOI: 10.1371/Journal.Pone.0046454  0.149
2021 Shiota M, Akamatsu S, Narita S, Sumiyoshi T, Fujiwara M, Uchiumi T, Ogawa O, Habuchi T, Eto M. The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer. The Pharmacogenomics Journal. PMID 33649516 DOI: 10.1038/s41397-021-00220-0  0.149
2015 Mizowaki T, Inokuchi H, Nakamura K, Norihisa Y, Kamba T, Inoue T, Ogawa O, Hiraoka M. Outcomes of High-Dose Whole-Pelvic IMRT With Simultaneous Integrated Boost in Patients With Pelvic Lymph Node–Positive Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 93: E188. DOI: 10.1016/J.IJROBP.2015.07.1029  0.149
2019 Negoro H, Goto T, Akamatsu S, Terada N, Kobayashi T, Matsui Y, Yamamoto T, Omura T, Yonezawa A, Matsubara K, Ogawa O. Add-on effects of tadalafil in tamsulosin-treated patients with small benign prostatic enlargement: A randomized, placebo-controlled, double-blind, crossover study. Neurourology and Urodynamics. PMID 31578771 DOI: 10.1002/nau.24175  0.149
2005 Kobayashi T, Kinoshita H, Nishizawa K, Mitsumori K, Ogawa O, Kamoto T. Age-associated increase of prostate-specific antigen in a high level of men visiting urological clinics. International Journal of Urology : Official Journal of the Japanese Urological Association. 12: 733-8. PMID 16174047 DOI: 10.1111/j.1442-2042.2005.01121.x  0.149
2021 Uemura H, Kobayashi K, Yokomizo A, Hinotsu S, Horie S, Kakehi Y, Naito S, Nonomura N, Ogawa O, Oya M, Suzuki K, Saito A, Uno S, Akaza H. Enzalutamide plus androgen deprivation therapy (ADT) versus flutamide plus ADT in men with castration-resistant prostate cancer (CRPC): AFTERCAB. Journal of Clinical Oncology. 39: 81-81. DOI: 10.1200/JCO.2021.39.6_SUPPL.81  0.149
2000 Kakehi Y, Kamoto T, Okuno H, Terai A, Terachi T, Ogawa O. Per-operative frozen section examination of pelvic nodes is unnecessary for the majority of clinically localized prostate cancers in the prostate-specific antigen era. International Journal of Urology : Official Journal of the Japanese Urological Association. 7: 281-6. PMID 10976815 DOI: 10.1046/j.1442-2042.2000.00191.x  0.149
2000 Sasaki R, Habuchi T, Sato K, Akao T, Kakinuma H, Zhang LQ, Wang L, Matsuo S, Sasaki S, Ogawa O, Kato T. The clinical utility of measuring total PSA, PSA density, gamma-seminoprotein and gamma-seminoprotein/total PSA in prostate cancer prediction. Japanese Journal of Clinical Oncology. 30: 337-42. PMID 11059338 DOI: 10.1093/JJCO/HYD089  0.149
2016 Hirayama K, Kobayashi T, Matsui Y, Inoue T, Kanba T, Ogawa O. PD13-11 LONGER INTERVAL BETWEEN DISEASE ONSET AND TREATMENT INITIATION IS ASSOCIATED WITH UNFAVORABLE PATHOLOGICAL AND ONCOLOGICAL OUTCOMES OF NEPHROURETERECTOMY FOR UPPER URINARY TRACT UROTHELIAL CANCER Journal of Urology. 195. DOI: 10.1016/J.JURO.2016.02.982  0.149
2021 Mizuno K, Sumiyoshi T, Okegawa T, Terada N, Ishitoya S, Miyazaki Y, Kojima T, Katayama H, Fujimoto N, Hatakeyama S, Shiota M, Yoshimura K, Matsui Y, Narita S, Matsumoto H, ... ... Ogawa O, et al. Clinical impact of detecting low-frequency variants in cell-free DNA on treatment of castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34526361 DOI: 10.1158/1078-0432.CCR-21-2328  0.148
2006 Nakamura E, Abreu-e-Lima P, Awakura Y, Inoue T, Kamoto T, Ogawa O, Kotani H, Manabe T, Zhang GJ, Kondo K, Nosé V, Kaelin WG. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. The American Journal of Pathology. 168: 574-84. PMID 16436671 DOI: 10.2353/Ajpath.2006.050867  0.148
2003 Nakamura E, Terachi T, Kamoto T, Okuno H, Terai A, Kakehi Y, Ogawa O. Retroperitoneoscopic ureterocutaneostomy for obstructive uropathy with advanced bladder cancer: a case report. International Journal of Urology : Official Journal of the Japanese Urological Association. 9: 60-2. PMID 11972653 DOI: 10.1046/j.1442-2042.2002.00420.x  0.148
1992 Habuchi T, Ogawa O, Kakehi Y, Ogura K, Koshiba M, Sugiyama T, Yoshida O. Allelic loss of chromosome 17p in urothelial cancer: strong association with invasive phenotype. The Journal of Urology. 148: 1595-9. PMID 1433575 DOI: 10.1016/S0022-5347(17)36977-X  0.148
2013 Akamatsu S, Takata R, Takahashi A, Kubo M, Haiman C, Henderson B, Fujioka T, Habuchi T, Nakamura Y, Ogawa O, Nakagawa H. 2234 A Common Genetic Variants Based Risk Prediction Model For Prostate Cancer Is Highly Reproducible In Japanese, And Compensates For Prostate Specific Antigen At Gray-Zone The Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2143  0.148
2020 Ishigaki K, Akiyama M, Kanai M, Takahashi A, Kawakami E, Sugishita H, Sakaue S, Matoba N, Low SK, Okada Y, Terao C, Amariuta T, Gazal S, Kochi Y, Horikoshi M, ... ... Ogawa O, et al. Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases. Nature Genetics. PMID 32514122 DOI: 10.1038/S41588-020-0640-3  0.147
2004 Wang L, Sato K, Tsuchiya N, Ohyama C, Satoh S, Ogawa O, Kato T, Habuchi T. 468: Polymorphic CA Repeats in IGF-I Gene is a Common Genetic Modifier in the Etiology of Prostate Cancer and Benign Prostatic Hyperplasia Journal of Urology. 171: 125-125. DOI: 10.1016/s0022-5347(18)37730-9  0.147
2018 Takata R, Akamatsu S, Nakagawa H, Terada N, Kato Y, Kanehira M, Sugimura J, Omori S, Abe T, Inazawa J, Ogawa O, Obara W. MP70-09 IDENTIFICATION OF NINE NEW SUSCEPTIBILITY LOCI FOR PROSTATE CANCER IN THE JAPANESE POPULATION Journal of Urology. 199. DOI: 10.1016/j.juro.2018.02.2253  0.147
2022 Uemura H, Kobayashi K, Yokomizo A, Hinotsu S, Horie S, Kakehi Y, Nonomura N, Ogawa O, Oya M, Suzuki K, Saito A, Asakawa K, Uno S, Naito S. Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study. International Journal of Clinical Oncology. PMID 35948732 DOI: 10.1007/s10147-022-02221-w  0.147
2017 Terada N, Maughan BL, Akamatsu S, Kobayashi T, Yamasaki T, Inoue T, Kamba T, Ogawa O, Antonarakis ES. Exploring optimal sequence of abiraterone and enzalutamide in patients with castration-resistant prostate cancer: The Kyoto-Baltimore collaboration. Journal of Clinical Oncology. 35: 219-219. DOI: 10.1200/JCO.2017.35.6_SUPPL.219  0.147
2019 Arai Y, Ogawa O. Hormone Therapy and Castration Resistance of Prostate Cancer. The Canadian Journal of Urology. 26: 9686. PMID 31012829  0.146
2015 Terada N, Terao C, Yoshimura K, Kobayashi T, Matsui Y, Inoue T, Kamba T, Matsuda F, Ogawa O. MP60-02 SINGLE NUCLEOTIDE POLYMORPHISMS IN SLC45A3 AND KLK3 ARE CORRELATED WITH SERUM PSA LEVELS AND ARE POTENTIAL BIOMARKERS FOR DETECTING PROSTATE CANCER Journal of Urology. 193. DOI: 10.1016/J.JURO.2015.02.2204  0.146
2013 Kita Y, Shimizu Y, Inoue T, Kamba T, Yoshimura K, Ogawa O. Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients. International Journal of Clinical Oncology. 18: 718-23. PMID 22791141 DOI: 10.1007/s10147-012-0443-3  0.146
2005 Takegami M, Suzukamo Y, Sanda MG, Kamoto T, Namiki S, Arai Y, Ogawa O, Fukuhara S, Kakehi Y. [The Japanese translation and cultural adaptation of Expanded Prostate Cancer Index Composite (EPIC)]. Nihon HinyåKika Gakkai Zasshi. the Japanese Journal of Urology. 96: 657-69. PMID 16363651  0.146
2006 Watanabe J, Nishiyama H, Matsui Y, Ito M, Kawanishi H, Kamoto T, Ogawa O. Dicoumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines. Oncogene. 25: 2500-8. PMID 16518417 DOI: 10.1038/sj.onc.1209162  0.145
2023 Nishiyama H, Tsuzuki T, Ohyama C, Matsuyama H, Shinozaki K, Hayashi Y, Hayashi N, Koto R, Shin E, Ogawa O. Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study. International Journal of Clinical Oncology. PMID 37498492 DOI: 10.1007/s10147-023-02386-y  0.145
2019 Sumiyoshi T, Mizuno K, Yamasaki T, Miyazaki Y, Makino Y, Okasho K, Li X, Utsunomiya N, Goto T, Kobayashi T, Terada N, Inoue T, Kamba T, Fujimoto A, Ogawa O, et al. Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer. Scientific Reports. 9: 4030. PMID 30858508 DOI: 10.1038/s41598-019-40719-y  0.145
2019 Fujiwara M, Akamatsu S, Sumiyoshi T, Segawa T, Mizuno K, Yoshino T, Goto T, Sawada A, Saito R, Kobayashi T, Yamasaki T, Inoue T, Ogawa O. Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer. PMID 31307917 DOI: 10.1016/j.clgc.2019.04.017  0.145
2019 Tanaka N, Nishimura K, Okajima E, Ina K, Ogawa O, Nagata H, Akakura K, Fujimoto K, Gotoh M, Teramukai S, Hirao Y. Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 31055879 DOI: 10.1111/Iju.14009  0.145
2021 Hussain SA, Shimizu N, Obara W, Yamasaki T, Takashima S, Hasegawa T, Iguchi M, Igarashi K, Ogawa O, Fujioka T. Phase II open-label study of S-588410 as maintenance monotherapy after first-line platinum-containing chemotherapy in patients with advanced or metastatic urothelial carcinoma. Journal of Clinical Oncology. 39: 440-440. DOI: 10.1200/JCO.2021.39.6_SUPPL.440  0.145
2015 Goto T, Terada N, Inoue T, Kobayashi T, Nakayama K, Okada Y, Yoshikawa T, Miyazaki Y, Uegaki M, Utsunomiya N, Makino Y, Sumiyoshi S, Yamasaki T, Kamba T, Ogawa O. Decreased expression of lysophosphatidylcholine (16: 0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer Prostate. DOI: 10.1002/pros.23088  0.145
2006 Matsui Y, Watanabe J, Nishiyama H, Kawanishi H, Ito M, Takahashi T, Kamoto T, Ogawa O. TRIPTOLIDE (PG490)-MEDIATED SENSITISATION OF UROTHELIAL CANCER CELLS TO CISPLATIN-INDUCED APOPTOSIS European Urology Supplements. 5: 112. DOI: 10.1016/S1569-9056(06)60365-5  0.145
2019 Imai K, Negoro H, Takashima Y, Goto T, Sawada A, Akamatsu S, Saito R, Kobayashi T, Yamasaki T, Inoue T, Ogawa O. [Post-Operative Urethral Stricture after Holmium Laser Enucleation of the Prostate]. Hinyokika Kiyo. Acta Urologica Japonica. 65: 445-449. PMID 31902176 DOI: 10.14989/ActaUrolJap_65_11_445  0.144
2023 Taniguchi H, Inoue T, Kawa G, Murota T, Tsukino H, Yoshimura K, Kamoto T, Ogawa O, Matsuda T, Kinoshita H. Evaluation of sexual function after dutasteride treatment in patients with once-negative prostate biopsy and benign prostate hyperplasia. Urologia. 3915603231163201. PMID 36992564 DOI: 10.1177/03915603231163201  0.144
2008 Nadaoka J, Horikawa Y, Saito M, Kumazawa T, Inoue T, Narita S, Yuasa T, Satoh S, Nishiyama H, Ogawa O, Tsuchiya N, Habuchi T. Prognostic significance of HIF-1 alpha polymorphisms in transitional cell carcinoma of the bladder. International Journal of Cancer. Journal International Du Cancer. 122: 1297-302. PMID 18000826 DOI: 10.1002/ijc.23256  0.144
2021 Kobayashi M, Narita S, Matsui Y, Kanda S, Hidaka Y, Abe H, Tsuzuki T, Ito K, Kojima T, Kato M, Hatakeyama S, Matsushita Y, Naito S, Shiga M, Miyake M, ... ... Ogawa O, et al. Impact of histological variants on outcomes in patients with urothelial cancer treated with pembrolizumab: a propensity score matching analysis. Bju International. PMID 34110696 DOI: 10.1111/bju.15510  0.144
1996 Okamoto K, Toyokuni S, Kim WJ, Ogawa O, Kakehi Y, Arao S, Hiai H, Yoshida O. Overexpression of human mutT homologue gene messenger RNA in renal-cell carcinoma: evidence of persistent oxidative stress in cancer. International Journal of Cancer. 65: 437-41. PMID 8621223 DOI: 10.1002/(SICI)1097-0215(19960208)65:4<437::AID-IJC7>3.0.CO;2-Y  0.144
2010 Matsui Y, Watanabe J, Ding S, Nishizawa K, Kajita Y, Ichioka K, Saito R, Kobayashi T, Ogawa O, Nishiyama H. Dicoumarol enhances doxorubicin-induced cytotoxicity in p53 wild-type urothelial cancer cells through p38 activation. Bju International. 105: 558-64. PMID 19583730 DOI: 10.1111/j.1464-410X.2009.08732.x  0.143
2008 Sengiku A, Nishiyama H, Shimizu T, Watabe J, Soda T, Kamba T, Yoshimura K, Kanematsu A, Nakamura E, Kamoto T, Ogawa O. [Post-operative recurrence patterns of urothelial tumors in the upper urinary tract: comparison between renal pelvic and ureteral tumors]. Hinyokika Kiyo. Acta Urologica Japonica. 54: 703-9. PMID 19068723  0.143
2020 Masuda N, Murakami K, Kita Y, Hamada A, Kamada M, Teramoto Y, Sakatani T, Matsumoto K, Sano T, Saito R, Okuno Y, Ogawa O, Kobayashi T. Trp53 mutation in Krt5-expressing basal cells facilitates the development of basal squamous-like invasive bladder cancer in the chemical carcinogenesis of mouse bladder. The American Journal of Pathology. PMID 32339497 DOI: 10.1016/j.ajpath.2020.04.005  0.143
1999 Arai Y, Okubo K, Aoki Y, Maekawa S, Okada T, Maeda H, Ogawa O, Kato T. Patient-reported quality of life after radical prostatectomy for prostate cancer. International Journal of Urology : Official Journal of the Japanese Urological Association. 6: 78-86. PMID 10226812 DOI: 10.1046/j.1442-2042.1999.00629.x  0.143
2022 Yamamoto K, Ioroi T, Shinomiya K, Yoshida A, Harada K, Fujisawa M, Omura T, Ikemi Y, Nakagawa S, Yonezawa A, Ogawa O, Matsubara K, Iwamoto T, Nishikawa K, Hayashi S, et al. STAT3 polymorphism associates with mTOR inhibitor-induced interstitial lung disease in patients with renal cell carcinoma. Oncology Research. PMID 35016744 DOI: 10.3727/096504022X16418911579334  0.142
2006 Kobayashi T, Inoue T, Shimizu Y, Segawa T, Kamoto T, Ogawa O. RHEB, A NOVEL SMALL G-PROTEIN OF RAS SUPERFAMILY, IS ASSOCIATED WITH PROLIFERATION IN HUMAN PROSTATE CANCER CELL LINES European Urology Supplements. 5: 124. DOI: 10.1016/S1569-9056(06)60411-9  0.142
2009 Inoue T, Maeno A, Kulkarni P, Zeng Y, Yeater DB, Leman ES, Ogawa O, Getzenberg RH. Purine-Rich Element Binding Protein Alpha Induces Cell Stress And Differentiation Pathways In Prostate Cancer Cells The Journal of Urology. 181: 189-189. DOI: 10.1016/S0022-5347(09)60545-0  0.142
2008 Shintaku I, Satoh M, Okajima E, Fujimoto H, Kamoto T, Ogawa O, Kawai K, Akaza H, Tsukamoto T, Naito S, Miki T, Arai Y. Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan. Japanese Journal of Clinical Oncology. 38: 281-7. PMID 18321891 DOI: 10.1093/jjco/hyn009  0.142
2007 Sano T, Nishiyama H, Kanematsu A, Takahashi T, Nakamura E, Kamoto T, Mikami Y, Koyama T, Ogawa O. [Solitary fibrous tumor in the pelvic space: a case report]. Hinyokika Kiyo. Acta Urologica Japonica. 53: 897-901. PMID 18203530  0.142
2007 Ito M, Nishiyama H, Kawanishi H, Matsui S, Guilford P, Reeve A, Ogawa O. P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer. The Journal of Urology. 178: 1073-9. PMID 17644138 DOI: 10.1016/j.juro.2007.05.012  0.142
2019 Inoue T, Kaneko T, Muramatsu S, Kimura H, Yoshino T, Goto T, Sawada A, Akamatsu S, Kobayashi T, Yamasaki T, Kaya T, Ogawa O. LacdiNAc-Glycosylated Prostate-specific Antigen Density is a Potential Biomarker of Prostate Cancer. Clinical Genitourinary Cancer. PMID 31711843 DOI: 10.1016/j.clgc.2019.10.011  0.142
2011 Mizowaki T, Norihisa Y, Ogura M, Kamba T, Inoue T, Shimizu Y, Ogawa O, Hiraoka M. Survival outcomes of neoadjuvant hormone therapy plus external-beam radiotherapy with relatively early initiation of salvage hormone therapy to patients with T3-4N0M0 prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 95. PMID 27968356 DOI: 10.1200/jco.2011.29.7_suppl.95  0.142
2009 Iguchi R, Kanematsu A, Nakamura E, Shimizu T, Watanabe J, Soda T, Kamba T, Yoshimura K, Nishiyama H, Kamoto T, Ogawa O. [Two-stage nephron-sparing surgery for bilateral T2 renal cell carcinoma and von Hippel-Lindau disease: a case report]. Hinyokika Kiyo. Acta Urologica Japonica. 55: 483-5. PMID 19764533  0.141
2011 Takata R, Akamatsu S, Nakagawa H, Kubo M, Tsunoda T, Inazawa J, Kamatani N, Ogawa O, Nakamura Y, Fujioka T. 144 GENOME-WIDE ASSOCIATION STUDY IDENTIFIES MULTIPLE NEW SUSCEPTIBILITY LOCI FOR PROSTATE CANCER IN JAPANESE POPULATION Journal of Urology. 185. DOI: 10.1016/J.JURO.2011.02.211  0.141
2019 Aizawa R, Takayama K, Nakamura K, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Ogawa O, Mizowaki T. Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy. International Journal of Clinical Oncology. PMID 31820209 DOI: 10.1007/s10147-019-01596-7  0.141
2010 Akamatsu S, Takata R, Ashikawa K, Hosono N, Kamatani N, Fujioka T, Ogawa O, Kubo M, Nakamura Y, Nakagawa H. A functional variant in NKX3.1 associated with prostate cancer susceptibility down-regulates NKX3.1 expression. Human Molecular Genetics. 19: 4265-72. PMID 20716579 DOI: 10.1093/hmg/ddq350  0.141
2004 Ito M, Habuchi T, Watanabe J, Higashi S, Nishiyama H, Wang L, Tsuchiya N, Kamoto T, Ogawa O. Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer. Urology. 64: 74-8. PMID 15245939 DOI: 10.1016/J.UROLOGY.2004.03.001  0.141
2003 Kinoshita H, Kamoto T, Mitsumori M, Kiyokawa T, Habuchi T, Kakehi Y, Hiraoka M, Ogawa O. [Therapeutic strategy for prostate specific antigen (PSA) failure after radical prostatectomy]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 30: 32-7. PMID 12557702  0.141
2021 Aizawa R, Nakamura K, Norihisa Y, Ogata T, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Ogawa O, Mizowaki T. Long-term safety of high-dose whole pelvic IMRT for high-risk localized prostate cancer through 10-year follow-up. International Journal of Clinical Oncology. PMID 34338920 DOI: 10.1007/s10147-021-02002-x  0.141
1995 Ogura K, Habuchi T, Yamada H, Ogawa O, Yoshida O. IMMUNOHISTOCHEMICAL ANALYSIS OF p53 AND PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) IN BLADDER CANCER: POSITIVE IMMUNOSTAINING AND RADIOSENSITIVITY International Journal of Urology. 2: 302-308. DOI: 10.1111/j.1442-2042.1995.tb00004.x  0.141
2003 Wu XX, Kakehi Y, Mizutani Y, Nishiyama H, Kamoto T, Megumi Y, Ito N, Ogawa O. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. International Journal of Cancer. 104: 409-17. PMID 12584736 DOI: 10.1002/ijc.10948  0.14
2016 Nakamura K, Mizowaki T, Inokuchi H, Ikeda I, Kamba T, Inoue T, Yamasaki T, Kobayashi T, Ogawa O, Hiraoka M. A Pilot Study of Hypofractionated Intensity Modulated Radiation Therapy Over 3 Weeks for Localized Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics. 96: E275. PMID 27674243 DOI: 10.1016/j.ijrobp.2016.06.1315  0.14
2006 Akakura K, Suzuki H, Ichikawa T, Fujimoto H, Maeda O, Usami M, Hirano D, Takimoto Y, Kamoto T, Ogawa O, Sumiyoshi Y, Shimazaki J, Kakizoe T. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Japanese Journal of Clinical Oncology. 36: 789-93. PMID 17082219 DOI: 10.1093/jjco/hyl115  0.14
2003 Wang L, Habuchi T, Mitsumori K, Li Z, Kamoto T, Kinoshita H, Tsuchiya N, Sato K, Ohyama C, Nakamura A, Ogawa O, Kato T. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. International Journal of Cancer. 103: 116-20. PMID 12455063 DOI: 10.1002/ijc.10793  0.14
2019 Sugiyama Y, Yatsuda J, Murakami Y, Ito N, Yamasaki T, Mikami Y, Ogawa O, Kamba T. Impact of tumor size on patient survival after radical nephrectomy for pathological T3a renal cell carcinoma. Japanese Journal of Clinical Oncology. PMID 30793163 DOI: 10.1093/jjco/hyy200  0.14
1997 Kinoshita H, Ogawa O, Kakehi Y, Mishina M, Mitsumori K, Itoh N, Yamada H, Terachi T, Yoshida O. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. Journal of the National Cancer Institute. 89: 724-30. PMID 9168188 DOI: 10.1093/JNCI/89.10.724  0.14
2020 Sato GE, Aizawa R, Nakamura K, Takayama K, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Ogawa O, Mizowaki T. Long-term clinical outcomes of salvage pelvic radiation therapy for oligo-recurrent pelvic lymph nodes after definitive external-beam radiation therapy for non-metastatic prostate cancer. Journal of Radiation Research. PMID 32583860 DOI: 10.1093/jrr/rraa044  0.14
2016 Arakaki R, Yamasaki T, Kanno T, Shibasaki N, Sakamoto H, Utsunomiya N, Sumiyoshi T, Shibuya S, Tsuruyama T, Nakamura E, Ogawa O, Kamba T. CCL2 as a potential therapeutic target for clear cell renal cell carcinoma. Cancer Medicine. PMID 27666332 DOI: 10.1002/cam4.886  0.14
2005 Matsui Y, Nishiyama H, Watanabe J, Teramukai S, Ono Y, Ohshima S, Fujimoto K, Hirao Y, Fukushima M, Ogawa O. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan. International Journal of Clinical Oncology. 10: 133-8. PMID 15864700 DOI: 10.1007/s10147-004-0474-5  0.139
2022 Akamatsu S, Terada N, Takata R, Kinoshita H, Shimatani K, Momozawa Y, Yamamoto M, Tada H, Kawamorita N, Narita S, Kato T, Nitta M, Kandori S, Koike Y, Inazawa J, ... ... Ogawa O, et al. Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy. Jnci Cancer Spectrum. 6: pkac001. PMID 35118230 DOI: 10.1093/jncics/pkac001  0.139
2016 Inoue T, Ogawa O. [Recent advancements in prostate cancer basic research]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 74: 7-12. PMID 26793872  0.139
2012 Ikeda I, Mizowaki T, Norihisa Y, Ogura M, Kamba T, Inoue T, Shimizu Y, Kamoto T, Ogawa O, Hiraoka M. EP-1125 OUTCOMES OF HIGH DOSE DYNAMIC CONFORMAL ARC IRRADIATION FOR PATIENTS WITH T1C-T2N0M0 PROSTATE CANCER Radiotherapy and Oncology. 103: S434. DOI: 10.1016/S0167-8140(12)71458-5  0.138
2002 Kakehi Y, Kamoto T, Kawakita M, Ogawa O. Follow-up of clinical stage I testicular cancer patients: cost and risk benefit considerations. International Journal of Urology : Official Journal of the Japanese Urological Association. 9: 154-60; discussion 1. PMID 12010325 DOI: 10.1046/j.1442-2042.2002.00440.x  0.138
2003 Kinoshita H, Ogawa O, Arai Y. [Laminectomy for spinal cord compression occurring in hormone refractory prostate cancer]. Hinyokika Kiyo. Acta Urologica Japonica. 48: 725-8. PMID 12512149  0.138
2006 Yoshida K, Nishiyama H, Kinoshita H, Matsuda T, Ogawa O. Surgical treatment for urethral recurrence after ileal neobladder reconstruction in patients with bladder cancer. Bju International. 98: 1008-11. PMID 17034603 DOI: 10.1111/j.1464-410X.2006.06422.x  0.138
2019 Mizuno K, Fujimoto A, Sumiyoshi T, Goto T, Kobayashi T, Yamasaki T, Inoue T, Ogawa O, Akamatsu S, Nakagawa H. A modified bioinformatics approach of detecting low-frequency mutations in cell-free DNA to achieve precision medicine for advanced prostate cancer European Urology Supplements. 18: e479. DOI: 10.1016/s1569-9056(19)30359-8  0.138
2001 Mizutani Y, Hongo F, Sato N, Ogawa O, Yoshida O, Miki T. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer. 92: 287-93. PMID 11466681 DOI: 10.1002/1097-0142(20010715)92:2<287::AID-CNCR1321>3.0.CO;2-4  0.138
2005 Higashi S, Matsui Y, Takahashi T, Nishiyama H, Ito N, Yamamoto S, Kamoto T, Ogawa O. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment]. Hinyokika Kiyo. Acta Urologica Japonica. 51: 529-31. PMID 16164268  0.138
2008 Awakura Y, Nakamura E, Ito N, Kamoto T, Ogawa O. Methylation-associated silencing of SFRP1 in renal cell carcinoma. Oncology Reports. 20: 1257-63. PMID 18949430  0.138
2018 Yoshida T, Kobayashi T, Ito K, Makita N, Matsuzaki T, Nakamoto T, Magaribuchi T, Kawa G, Kawaura T, Kitawaki T, Kawakita M, Ogawa O, Murota T, Kinoshita H, Matsuda T. Preoperative nomogram for predicting locally advanced disease in patients with upper urinary tract urothelial carcinoma European Urology Supplements. 17: e1619. DOI: 10.1016/s1569-9056(18)31969-9  0.138
2007 Kobayashi T, Goto R, Ito K, Ogawa O. 197: Prostate Cancer Screening Strategies with Rescreening Interval Determined by Individual Baseline Prostate-Specific Antigen Values are Cost-Effective Journal of Urology. 177: 66-66. DOI: 10.1016/S0022-5347(18)30462-2  0.137
2007 Yoshimura K, Kamoto T, Nakamura E, Segawa T, Kamba T, Takahashi T, Nishiyama H, Ito N, Takayama K, Mizowaki T, Mitsumori M, Hiraoka M, Ogawa O. Health-related quality-of-life after external beam radiation therapy for localized prostate cancer: intensity-modulated radiation therapy versus conformal radiation therapy. Prostate Cancer and Prostatic Diseases. 10: 288-92. PMID 17160068 DOI: 10.1038/sj.pcan.4500923  0.137
2016 Mizowaki T, Norihisa Y, Takayama K, Ikeda I, Inokuchi H, Nakamura K, Kamba T, Inoue T, Kamoto T, Ogawa O, Hiraoka M. Ten-year outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for intermediate- and high-risk patients with T1c-T2N0M0 prostate cancer. International Journal of Clinical Oncology. PMID 26843024 DOI: 10.1007/s10147-016-0954-4  0.137
2017 Kobayashi T, Kanao K, Araki M, Terada N, Kobayashi Y, Sawada A, Inoue T, Ebara S, Watanabe T, Kamba T, Sumitomo M, Nasu Y, Ogawa O. Impact of a robotic surgical system on treatment choice for men with clinically organ-confined prostate cancer. International Journal of Clinical Oncology. PMID 29127531 DOI: 10.1007/s10147-017-1203-1  0.137
2017 Saito R, Smith C, Kardos J, Bixby L, Chai S, Damrauer J, Utsumi T, Wobker S, Krishnan B, Ogawa O, Vincent B, Kim W. Mp88-20 Establishment Of Novel Mouse Bladder Cancer Cell Lines Mimicking Intrinsic Subtype Of Human Invasive Bladder Cancer The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2745  0.136
2018 Kubota M, Yamasaki T, Teramoto Y, Ito K, Takada H, Magaribuchi T, Sawada A, Akamatsu S, Negoro H, Saito R, Kobayashi T, Terada N, Inoue T, Kamba T, Ogawa O. [Two Cases of Metastatic and Recurrent Non-Clear Cell Renal Cell Carcinoma Re-Diagnosed as Renal Mucinous Tubular and Spindle Cell Carcinoma during Long-Term Follow-Up]. Hinyokika Kiyo. Acta Urologica Japonica. 64: 111-115. PMID 29684960  0.136
2016 Inoue T, Mizuno K, Kinoshita H, Yano T, Kawanishi H, Kanda H, Terada N, Kamba T, Okumura K, Kawakita M, Ogura K, Sugimura Y, Matsuda T, Ogawa O. MP57-08 PROSTATE-SPECIFIC ANTIGEN DENSITY IS THE MOST APPROPRIATE FACTOR FOR DETECTING UNFAVORABLE PATHOLOGY AFTER RADICAL PROSTATECTOMY IN MEN ELIGIBLE FOR ACTIVE SURVEILLANCE FROM MUTLI-INSTITUTIONAL STUDY Journal of Urology. 195. DOI: 10.1016/J.JURO.2016.02.662  0.136
2015 Burnier A, Shimizu Y, Dai Y, Nakashima M, Matsui Y, Ogawa O, Rosser CJ, Furuya H. CXCL1 is elevated in the urine of bladder cancer patients. Springerplus. 4: 610. PMID 26543745 DOI: 10.1186/s40064-015-1393-9  0.136
2015 Sun D, Sawada A, Nakashima M, Kobayashi T, Ogawa O, Matsui Y. MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway. Urologic Oncology. 33: 111.e17-26. PMID 25499922 DOI: 10.1016/j.urolonc.2014.10.018  0.136
2018 Masuda N, Ogawa O, Park M, Liu AY, Goodison S, Dai Y, Kozai L, Furuya H, Lotan Y, Rosser CJ, Kobayashi T. Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer. Oncotarget. 9: 7101-7111. PMID 29467953 DOI: 10.18632/oncotarget.23872  0.136
2010 Tsuchiya N, Narita S, Ma Z, Horikawa Y, Tsuruta H, Numakura K, Saito M, Satoh S, Inoue T, Ogawa O, Habuchi T. 2052 INSULIN-LIKE GROWTH FACTOR-I (IGF-I) POLYMORPHISMS PREDICT THE SURVIVAL OF PROSTATE CANCER PATIENTS WITH BONE METASTASIS AT INITIAL PRESENTATION Journal of Urology. 183. DOI: 10.1016/J.JURO.2010.02.2099  0.135
2019 Aizawa R, Takayama K, Nakamura K, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Ogawa O, Mizowaki T. Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation. International Journal of Clinical Oncology. PMID 31152322 DOI: 10.1007/s10147-019-01478-y  0.135
2015 Mizowaki T, Norihisa Y, Takayama K, Ikeda I, Inokuchi H, Nakamura K, Kamba T, Inoue T, Kamoto T, Ogawa O, Hiraoka M. Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer. International Journal of Clinical Oncology. PMID 26141133 DOI: 10.1007/s10147-015-0867-7  0.135
2022 Nakamura K, Norihisa Y, Ikeda I, Inokuchi H, Aizawa R, Kamoto T, Kamba T, Inoue T, Yamasaki T, Akamatsu S, Kobayashi T, Ogawa O, Mizowaki T. Ten-year outcomes of whole-pelvic intensity-modulated radiation therapy for prostate cancer with regional lymph node metastasis. Cancer Medicine. PMID 36536528 DOI: 10.1002/cam4.5554  0.135
2007 Kanematsu A, Yamamoto S, Ogawa O. Changing concepts of bladder regeneration. International Journal of Urology : Official Journal of the Japanese Urological Association. 14: 673-8. PMID 17681053 DOI: 10.1111/j.1442-2042.2007.01768.x  0.134
2006 Takahashi T, Higashi S, Nishiyama H, Segawa T, Nakamura E, Kinoshita H, Itoh N, Yamamoto S, Kamoto T, Habuchi T, Ogawa O. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen. Japanese Journal of Clinical Oncology. 36: 104-8. PMID 16418182 DOI: 10.1093/jjco/hyi220  0.134
2015 Nishikawa N, Yago R, Yamazaki Y, Negoro H, Suzuki M, Imamura M, Toda Y, Tanabe K, Ogawa O, Kanematsu A. Expression of parathyroid hormone/parathyroid hormone-related peptide receptor 1 in normal and diseased bladder detrusor muscles: a clinico-pathological study. Bmc Urology. 15: 2. PMID 25604159 DOI: 10.1186/1471-2490-15-2  0.134
2009 Mizowaki T, Takayama K, Norihisa Y, Yano S, Kamoto T, Nakamura E, Kamba T, Inoue T, Ogawa O, Hiraoka M. High Dose Local Irradiation to T3-4N0M0 Prostate Cancer with Intensity-modulated Radiotherapy Combined with Neoadjuvant Hormonal Therapy International Journal of Radiation Oncology*Biology*Physics. 75: S353-S354. DOI: 10.1016/J.IJROBP.2009.07.811  0.134
2013 Kobayashi T, Goto R, Hinotsu S, Ogawa O. [Socioeconomic advantages of longer screening intervals for men with low prostate-specific antigen levels in prostate cancer mass screening]. Hinyokika Kiyo. Acta Urologica Japonica. 59: 159-66. PMID 23633630  0.134
2014 Kamba T, Yamasaki T, Teramukai S, Shibasaki N, Arakaki R, Sakamoto H, Matsui Y, Okubo K, Yoshimura K, Ogawa O. Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice. International Journal of Clinical Oncology. 19: 505-15. PMID 23813043 DOI: 10.1007/s10147-013-0581-2  0.134
2018 Fukunaga A, Yamasaki T, Okuno T, Imai K, Ikeuchi R, Hishiki K, Goto T, Sawada A, Negoro H, Akamatsu S, Saito R, Kobayashi T, Inoue T, Ogawa O. [Initial Clinical Experience of Nivolumab for Metastatic Renal Cell Carcinoma]. Hinyokika Kiyo. Acta Urologica Japonica. 64: 383-389. PMID 30543735 DOI: 10.14989/ActaUrolJap_64_10_383  0.133
2010 Sakamoto M, Mizowaki T, Mitsumori M, Takayama K, Sasai K, Norihisa Y, Kamoto T, Nakamura E, Ogawa O, Hiraoka M. Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy in Japanese patients with locally advanced prostate cancer. International Journal of Clinical Oncology. 15: 571-7. PMID 20652347 DOI: 10.1007/s10147-010-0109-y  0.133
2017 Tanaka N, Nishimura K, Okajima E, Ina K, Ogawa O, Nagata H, Akakura K, Fujimoto K, Gotoh M, Teramukai S, Hirao Y. The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial. Japanese Journal of Clinical Oncology. PMID 28042138 DOI: 10.1093/Jjco/Hyw193  0.133
2014 Goto T, Terada N, Inoue T, Nakayama K, Yoshikawa T, Miyazaki Y, Uegaki M, Kobayashi T, Kamba T, Yoshimura K, Ogawa O. 110 The expression profile of phosphatidylinositol in high resolution imaging mass spectrometry is a potential biomarker for prostate cancer European Urology Supplements. 13: e110-e110a. DOI: 10.1016/S1569-9056(14)60111-1  0.133
2007 Kinoshita H, Kamoto T, Nishiyama H, Nakamura E, Matsuda T, Ogawa O. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males. International Journal of Urology : Official Journal of the Japanese Urological Association. 14: 930-4; discussion 93. PMID 17880291 DOI: 10.1111/j.1442-2042.2007.01858.x  0.133
2000 Habuchi T, Kakehi Y, Terachi T, Ogawa O, Yoshida O. [The prognostic value of adjuvant and neoadjuvant chemotherapy in total cystectomy for locally advanced bladder cancer]. Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology. 90: 809-17. PMID 10565159 DOI: 10.5980/JPNJUROL1989.90.809  0.132
2008 Terada N, Tsuchiya N, Ma Z, Shimizu Y, Kobayashi T, Nakamura E, Kamoto T, Habuchi T, Ogawa O. Association of genetic polymorphisms at 8q24 with the risk of prostate cancer in a Japanese population. The Prostate. 68: 1689-95. PMID 18726982 DOI: 10.1002/pros.20831  0.132
2012 Takata R, Akamatsu S, Nakagawa H, Takahashi A, Ha N, Kubo M, Habuchi T, Ogawa O, Nakamura Y, Fujioka T. 322 RISK ESTIMATION MODEL WITH MULTIPLE COMMON GENETIC VARIANTS FOR JAPANESE PROSTATE CANCER Journal of Urology. 187. DOI: 10.1016/J.JURO.2012.02.382  0.132
2018 Szarvas T, Nyirády P, Kobayashi T, Ogawa O, Rosser CJ, Furuya H. Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma. Methods in Molecular Biology (Clifton, N.J.). 1655: 251-273. PMID 28889391 DOI: 10.1007/978-1-4939-7234-0_19  0.132
2003 Kobayashi T, Kamoto T, Isogawa Y, Kinoshita H, Terai A, Habuchi T, Ogawa O, Kamato T. Ratio of prostate specific antigen minor molecular forms-to-total prostate specific antigen is constant regardless of the pathological condition of the prostate. The Journal of Urology. 169: 121-4. PMID 12478118 DOI: 010.1097/01.ju.0000041415.84858.3c  0.132
2013 Sakatani T, Matsui Y, Okubo K, Kamba T, Yoshimura K, Ogawa O. A case of secondary extramammary Paget's disease that occurred around the cutaneous stoma of ureterostomy Japanese Journal of Clinical Urology. 67: 611-615.  0.132
2019 Hattahara K, Yamasaki T, Sawada A, Tanigaki K, Endo S, Teramoto Y, Banno H, Fuchigami Y, Suzuki R, Fujiwara M, Hida T, Yoshino T, Kita Y, Goto T, Akamatsu S, ... ... Ogawa O, et al. [A Case of Late Onset Nivolumab-Induced Interstitial Nephritis in a Patient with Metastatic Renal Cell Carcinoma]. Hinyokika Kiyo. Acta Urologica Japonica. 65: 157-161. PMID 31247693 DOI: 10.14989/ActaUrolJap_65_5_157  0.132
2013 Matsuoka T, Sugino Y, Kobayashi T, Terada N, Yamasaki T, Matsui Y, Imamura M, Okubo K, Kamba T, Yoshimura K, Ogawa O. A case of prostate carcinosarcoma successfully treated with combined modality therapy Acta Urologica Japonica. 59: 749-752.  0.131
2014 Ghandour R, Danzig M, Rothberg M, RoyChoudhury A, Inoue T, Ogawa O, Kobayashi T, Kamba T, Badani K, McKiernan J. Mp2-19 Substratification Of D'Amico High Risk Prostate Cancer Reveals Clinically Distinct Populations: An American Validation Of The Japanese Model The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.177  0.131
2018 Aizawa R, Takayama K, Nakamura K, Inoue T, Kobayashi T, Akamatsu S, Yamasaki T, Ogawa O, Mizowaki T. Long-term outcomes of definitive external-beam radiotherapy for non-metastatic castration-resistant prostate cancer. International Journal of Clinical Oncology. PMID 29556917 DOI: 10.1007/s10147-018-1265-8  0.131
1998 Ogura K, Fukuzawa S, Habuchi T, Ogawa O, Yoshida O. Correlation of nuclear morphometry and immunostaining for p53 and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder. International Journal of Urology : Official Journal of the Japanese Urological Association. 4: 561-6. PMID 9477184 DOI: 10.1111/j.1442-2042.1997.tb00309.x  0.131
2003 KOBAYASHI T, KAMATO T, ISOGAWA Y, KINOSHITA H, TERAI A, HABUCHI T, OGAWA O. Ratio Of Prostate Specific Antigen Minor Molecular Forms-To-Total Prostate Specific Antigen Is Constant Regardless Of The Pathological Condition Of The Prostate Journal of Urology. 169: 121-124. DOI: 10.1016/S0022-5347(05)64050-5  0.131
2011 Miyazaki Y, Kamba T, Shimizu Y, Inoue T, Okubo K, Watanabe J, Yoshimura K, Kanematsu A, Nishiyama H, Ogawa O. [A case of amyloidosis of the ureter caused by primary macroglobulinemia]. Hinyokika Kiyo. Acta Urologica Japonica. 57: 185-8. PMID 21646848  0.131
2002 Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, Kakehi Y, Kakinuma H, Sato K, Nakamura A, Ogawa O, Kato T. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 23: 257-64. PMID 11872630 DOI: 10.1093/CARCIN/23.2.257  0.131
2017 Inoue T, Mizowaki T, Kabata D, Shintani A, Terada N, Yamasaki T, Negoro H, Kobayashi T, Nakamura K, Inokuchi H, Ogawa O. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study. Clinical Genitourinary Cancer. PMID 29051056 DOI: 10.1016/j.clgc.2017.09.009  0.13
2008 Kawanishi H, Matsui Y, Ito M, Watanabe J, Takahashi T, Nishizawa K, Nishiyama H, Kamoto T, Mikami Y, Tanaka Y, Jung G, Akiyama H, Nobumasa H, Guilford P, Reeve A, ... ... Ogawa O, et al. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2579-87. PMID 18451219 DOI: 10.1158/1078-0432.CCR-07-1922  0.13
2022 Makino Y, Kamiyama Y, Brown JB, Tanaka T, Murakami R, Teramoto Y, Goto T, Akamatsu S, Terada N, Inoue T, Kodama T, Ogawa O, Kobayashi T. Author Correction: Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1. Communications Biology. 5: 718. PMID 35854103 DOI: 10.1038/s42003-022-03707-z  0.129
2019 Takata R, Takahashi A, Fujita M, Momozawa Y, Saunders EJ, Yamada H, Maejima K, Nakano K, Nishida Y, Hishida A, Matsuo K, Wakai K, Yamaji T, Sawada N, Iwasaki M, ... ... Ogawa O, et al. 12 new susceptibility loci for prostate cancer identified by genome-wide association study in Japanese population. Nature Communications. 10: 4422. PMID 31562322 DOI: 10.1038/S41467-019-12267-6  0.129
2012 Mizowaki T, Takayama K, Norihisa Y, Ogura M, Kamba T, Inoue T, Shimizu Y, Kamoto T, Ogawa O, Hiraoka M. Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy for Japanese patients with T1c-T2N0M0 prostate cancer. International Journal of Clinical Oncology. 17: 562-8. PMID 21968911 DOI: 10.1007/s10147-011-0326-z  0.129
2016 Matsumoto K, Matsui Y, Negoro H, Terada N, Yamasaki T, Inoue T, Kamba T, Ogawa O, Kobayashi T. Guideline Adherence of Immediate Post-Transurethral Resection Intravesical Chemotherapy for Patients with Nonmuscle Invasive Bladder Cancer. Urology Practice. 3: 456-461. PMID 37592583 DOI: 10.1016/j.urpr.2015.10.003  0.129
2016 Matsumoto K, Matsui Y, Negoro H, Terada N, Yamasaki T, Inoue T, Kamba T, Ogawa O, Kobayashi T. Guideline Adherence of Immediate Post-Transurethral Resection Intravesical Chemotherapy for Patients with Nonmuscle Invasive Bladder Cancer. Urology Practice. 3: 456-461. PMID 37592583 DOI: 10.1016/j.urpr.2015.10.003  0.129
2015 Fukui T, Terada N, Takeda M, Inoue T, Kamba T, Yoshimura K, Chen F, Ogawa O. Thymic cancer mimicking a metastasis of testicular seminoma. International Cancer Conference Journal. 5: 45-47. PMID 31149422 DOI: 10.1007/s13691-015-0223-9  0.129
2007 Kawanishi H, Matsui Y, Yamasaki T, Takahashi T, Nishiyama H, Kamoto T, Tanaka Y, Jung G, Akiyama H, Nobumasa H, Nakamura E, Ogawa O. 775: Cell Culture Proteome Identifies CXCL 1 as a Secreted Marker and Mediator for the Tumor Invasion of Bladder Cancer Journal of Urology. 177: 260-260. DOI: 10.1016/S0022-5347(18)31015-2  0.128
2018 Kita Y, Goto T, Akamatsu S, Yamasaki T, Inoue T, Ogawa O, Kobayashi T. Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges. Cancers. 10. PMID 30248934 DOI: 10.3390/cancers10100345  0.128
2018 Ito K, Takashima Y, Akamatsu S, Terada N, Kobayashi T, Yamasaki T, Inoue T, Kamba T, Ogawa O, Negoro H. Intravesical prostatic protrusion is not always the same shape: Evaluation by preoperative cystoscopy and outcome in HoLEP. Neurourology and Urodynamics. PMID 30095172 DOI: 10.1002/nau.23428  0.128
2011 Ratanajaraya C, Nishiyama H, Takahashi M, Kawaguchi T, Saito R, Mikami Y, Suyama M, Lathrop M, Yamada R, Ogawa O, Matsuda F. A polymorphism of the POLG2 gene is genetically associated with the invasiveness of urinary bladder cancer in Japanese males. Journal of Human Genetics. 56: 572-6. PMID 21734712 DOI: 10.1038/Jhg.2011.60  0.128
2008 Kohei N, Kinoshita H, Kamoto T, Terai A, Kakehi Y, Ogawa O. Late relapse of testicular cancer 21 years after first complete remission: a case report. Hinyokika Kiyo. Acta Urologica Japonica. 54: 39-42. PMID 18260359  0.128
2008 Yamamoto S, Ishitoya S, Segawa T, Kamoto T, Okumura K, Ogawa O. Antibiotic prophylaxis for transrectal prostate biopsy: a prospective randomized study of tosufloxacin versus levofloxacin. International Journal of Urology : Official Journal of the Japanese Urological Association. 15: 604-6. PMID 18462354 DOI: 10.1111/j.1442-2042.2008.02056.x  0.128
1999 Mitsumori K, Terai A, Oka H, Segawa T, Ogura K, Yoshida O, Ogawa O. Androgen receptor CAG repeat length polymorphism in benign prostatic hyperplasia (BPH): correlation with adenoma growth. The Prostate. 41: 253-7. PMID 10544298 DOI: 10.1002/(SICI)1097-0045(19991201)41:4<253::AID-PROS5>3.0.CO;2-9  0.128
2019 Kuroiwa K, Inokuchi J, Nishiyama H, Kojima T, Kakehi Y, Sugimoto M, Tanigawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Ohyama C, Yokomizo A, Matsuyama H, et al. Impact of Previous, Simultaneous or Subsequent Bladder Cancer on Prognosis after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma. The Journal of Urology. 101097JU000000000000. PMID 31251717 DOI: 10.1097/JU.0000000000000422  0.128
1995 Kinoshita H, Yamada H, Ogawa O, Kakehi Y, Osaka M, Nakamura E, Mishina M, Habuchi T, Takahashi R, Sugiyama T. Contribution of chromosome 9p21-22 deletion to the progression of human renal cell carcinoma. Japanese Journal of Cancer Research : Gann. 86: 795-9. PMID 7591954 DOI: 10.1111/J.1349-7006.1995.TB03087.X  0.127
2014 Terao C, Terada N, Matsuo K, Kawaguchi T, Yoshimura K, Hayashi N, Shimizu M, Soga N, Takahashi M, Kotoura Y, Yamada R, Ogawa O, Matsuda F. A genome-wide association study of serum levels of prostate-specific antigen in the Japanese population. Journal of Medical Genetics. 51: 530-6. PMID 24919509 DOI: 10.1136/jmedgenet-2014-102423  0.127
2004 Nishiyama H, Habuchi T, Watanabe J, Teramukai S, Tada H, Ono Y, Ohshima S, Fujimoto K, Hirao Y, Fukushima M, Ogawa O. Clinical outcome of a large-scale multi-institutional retrospective study for locally advanced bladder cancer: a survey including 1131 patients treated during 1990-2000 in Japan. European Urology. 45: 176-81. PMID 14734003 DOI: 10.1016/J.EURURO.2003.09.011  0.127
2021 Taoka R, Kobayashi T, Hidaka Y, Abe H, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, ... ... Ogawa O, et al. Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma. Urologic Oncology. PMID 34454824 DOI: 10.1016/j.urolonc.2021.08.002  0.127
2009 Shiraishi Y, Yoshimura K, Inoue T, Okubo K, Watanabe J, Kamba T, Kanematsu A, Nakamura E, Nishiyama H, Kamoto T, Ogawa O. [One year follow-up results of urinary incontinence and sexual function after holmium laser enucleation of the prostate]. Hinyokika Kiyo. Acta Urologica Japonica. 55: 539-43. PMID 19827614  0.127
2020 Yoshida T, Kobayashi T, Kawaura T, Miyake M, Ito K, Okuno H, Murota T, Makita N, Kawakita M, Kawa G, Kitawaki T, Fujimoto K, Matsuyama H, Shiina H, Azuma H, ... Ogawa O, et al. Development and external validation of a preoperative nomogram for predicting pathological locally advanced disease of clinically localized upper urinary tract carcinoma. Cancer Medicine. PMID 32253820 DOI: 10.1002/cam4.2988  0.127
2019 Mizuno K, Akamatsu S, Sumiyoshi T, Wong JH, Fujita M, Maejima K, Nakano K, Ono A, Aikata H, Ueno M, Hayami S, Yamaue H, Chayama K, Inoue T, Ogawa O, et al. eVIDENCE: a practical variant filtering for low-frequency variants detection in cell-free DNA. Scientific Reports. 9: 15017. PMID 31641155 DOI: 10.1038/s41598-019-51459-4  0.126
2014 Mizowaki T, Takayama K, Norihisa Y, Ikeda I, Kamba T, Kamoto T, Inoue T, Nakamura E, Ogawa O, Hiraoka M. EP-1309: Long-term outcome of IMRT with neoadjuvant hormonal therapy under early salvage policy for T3-4N0M0 prostate cancer Radiotherapy and Oncology. 111: S91. DOI: 10.1016/S0167-8140(15)31427-4  0.126
2001 Mizutani Y, Wada H, Ogawa O, Yoshida O, Fukushima M, Nonomura N, Miki T. Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer. 92: 510-8. PMID 11505394 DOI: 10.1002/1097-0142(20010801)92:3<510::AID-CNCR1349>3.0.CO;2-0  0.126
2009 Zhong Y, Onuki J, Yamasaki T, Ogawa O, Akatsuka S, Toyokuni S. Genome-wide analysis identifies a tumor suppressor role for aminoacylase 1 in iron-induced rat renal cell carcinoma. Carcinogenesis. 30: 158-64. PMID 19028700 DOI: 10.1093/carcin/bgn255  0.126
2019 Saito R, Kobayashi T, Kashima S, Matsumoto K, Ogawa O. Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology. International Journal of Clinical Oncology. PMID 31407168 DOI: 10.1007/s10147-019-01520-z  0.126
2011 Eto M, Kamba T, Miyake H, Fujisawa M, Yoshida K, Uemura H, Tsukamoto T, Katsuoka Y, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S. An analysis of STAT3 polymorphism on outcomes of interferon-alpha treatment in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4590. PMID 28023784 DOI: 10.1200/jco.2011.29.15_suppl.4590  0.126
2022 Takahashi S, Narita S, Fujiyama N, Hatakeyama S, Kobayashi T, Kato R, Naito S, Sakatani T, Kashima S, Koizumi A, Yamamoto R, Taketoshi N, Kanda S, Numakura K, Saito M, ... ... Ogawa O, et al. Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab. Cancer Science. PMID 35848083 DOI: 10.1111/cas.15488  0.126
2011 Mizowaki T, Norihisa Y, Ogura M, Kamba T, Inoue T, Shimizu Y, Kamoto T, Yano S, Ogawa O, Hiraoka M. 7030 POSTER Outcomes of Intensity-Modulated Radiation Therapy Combined With Neoadjuvant Hormonal Therapy for High-risk Prostate Cancer European Journal of Cancer. 47: S493. DOI: 10.1016/S0959-8049(11)71981-5  0.126
2008 Holyoake A, O'Sullivan P, Pollock R, Best T, Watanabe J, Kajita Y, Matsui Y, Ito M, Nishiyama H, Kerr N, da Silva Tatley F, Cambridge L, Toro T, Ogawa O, Guilford P. Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 742-9. PMID 18245534 DOI: 10.1158/1078-0432.CCR-07-1672  0.125
2015 Shibasaki N, Yamasaki T, Kanno T, Arakaki R, Sakamoto H, Utsunomiya N, Inoue T, Tsuruyama T, Nakamura E, Ogawa O, Kamba T. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. Plos One. 10: e0130980. PMID 26114873 DOI: 10.1371/journal.pone.0130980  0.125
2008 Horikawa Y, Nadaoka J, Saito M, Kumazawa T, Inoue T, Yuasa T, Tsuchiya N, Nishiyama H, Ogawa O, Habuchi T. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncology Reports. 20: 49-55. PMID 18575717  0.125
2008 Tamaki M, Nakashima M, Nishiyama R, Ikeda H, Hiura M, Kanaoka T, Nakano T, Hayashi T, Ogawa O. [Assessment of clinical usefulness of Eviprostat for benign prostatic hyperplasia--comparison of Eviprostat tablet with a formulation containing two-times more active ingredients]. Hinyokika Kiyo. Acta Urologica Japonica. 54: 435-45. PMID 18634442  0.125
1999 Ohgaki K, Iida A, Ogawa O, Kubota Y, Akimoto M, Emi M. Localization of tumor suppressor gene associated with distant metastasis of urinary bladder cancer to a 1-Mb interval on 8p22. Genes, Chromosomes & Cancer. 25: 1-5. PMID 10221333 DOI: 10.1002/(SICI)1098-2264(199905)25:1<1::AID-GCC1>3.0.CO;2-3  0.125
2012 Akamatsu S, Takata R, Haiman C, Inoue T, Takahashi A, Kubo M, Furihata M, Kamatani N, Inazawa J, Chen G, Marchand L, Kolonel L, Yamada H, Egawa S, Fujioka T, ... ... Ogawa O, et al. 434 Four loci at 11q12, 10q26, 3p11.2, and 2p11 are associated with prostate cancer susceptibility in the Japanese population European Urology Supplements. 11: e434-e434a. DOI: 10.1016/S1569-9056(12)60431-X  0.125
2011 Hinotsu S, Akaza H, Usami M, Ogawa O, Kitamura T, Suzuki K, Tsukamoto T, Naito S, Namiki M, Hirao Y, Murai M. MP-16.14 Improved Grouping System Combining Gleason Score for Group IV of TNM Prognostic Grouping for Prostate Cancer: Results from J-CAP Database Urology. 78: S152. DOI: 10.1016/J.UROLOGY.2011.07.382  0.124
2010 Shinsako K, Mizuno T, Terada T, Watanabe J, Kamba T, Nakamura E, Ogawa O, Inui K. Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study. International Journal of Clinical Oncology. 15: 512-4. PMID 20340037 DOI: 10.1007/s10147-010-0070-9  0.124
2014 Fukui T, Yamasaki T, Mizuno K, Negoro H, Kobayashi T, Terada N, Sugino Y, Matsui Y, Inoue T, Kamba T, Yoshimura K, Ogawa O. [A case of late perirenal fat recurrence after partial nephrectomy for T1A renal cell carcinoma]. Hinyokika Kiyo. Acta Urologica Japonica. 60: 481-3. PMID 25391777  0.124
2006 Teramukai S, Nishiyama H, Matsui Y, Ogawa O, Fukushima M. Evaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadjuvant chemotherapy in invasive bladder cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 139-43. PMID 16397035 DOI: 10.1158/1078-0432.CCR-05-1598  0.124
2006 Kanamaru S, Kurazono H, Terai A, Monden K, Kumon H, Mizunoe Y, Ogawa O, Yamamoto S. Increased biofilm formation in Escherichia coli isolated from acute prostatitis. International Journal of Antimicrobial Agents. 28: S21-5. PMID 16828264 DOI: 10.1016/j.ijantimicag.2006.05.006  0.124
2019 Ito K, Furuta A, Kido A, Teramoto Y, Akamatsu S, Terada N, Yamasaki T, Inoue T, Ogawa O, Kobayashi T. Detectability of prostate cancer in different parts of the gland with 3-Tesla multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. International Journal of Clinical Oncology. PMID 31792635 DOI: 10.1007/s10147-019-01587-8  0.124
2016 Kawano Y, Takahashi W, Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S. Prognosis of metastatic renal cell carcinoma with first-line Interferon-α therapy in the era of molecular-targeted therapy. Cancer Science. PMID 27089226 DOI: 10.1111/Cas.12951  0.124
2007 Jiko M, Yano I, Sato E, Takahashi K, Motohashi H, Masuda S, Okuda M, Ito N, Nakamura E, Segawa T, Kamoto T, Ogawa O, Inui K. Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. International Journal of Clinical Oncology. 12: 284-90. PMID 17701008 DOI: 10.1007/s10147-007-0681-y  0.124
2019 Murakami K, Hamada A, Teramoto Y, Matsumoto K, Kita Y, Saito R, Yamasaki T, Matsui Y, Inoue T, Ogawa O, Kobayashi T. Efficacy of Immediate Postoperative Instillation of Chemotherapy for Primary Non-Muscle-Invasive Bladder Cancer in Real-World Clinical Practice. Clinical Genitourinary Cancer. PMID 31402280 DOI: 10.1016/j.clgc.2019.05.028  0.124
2004 Kawahara T, Nishiyama H, Okubo K, Ito N, Kinoshita H, Yamamoto S, Kamoto T, Ogawa O. [Right ectopic ureter with ipsilateral renal agenesis presenting with infertility: a case report]. Hinyokika Kiyo. Acta Urologica Japonica. 50: 435-8. PMID 15293745  0.124
2004 Ishitoya S, Kurazono H, Nishiyama H, Nakamura E, Kamoto T, Habuchi T, Terai A, Ogawa O, Yamamoto S. Verotoxin induces rapid elimination of human renal tumor xenografts in SCID mice. The Journal of Urology. 171: 1309-13. PMID 14767339 DOI: 10.1097/01.JU.0000100110.11129.85  0.123
2003 Habuchi T, Kamoto T, Hara I, Kawai K, Nakao M, Nonomura N, Kobayashi T, Ogawa O, Kamidono S, Akaza H, Okuyama A, Kato T, Miki T. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers. Cancer. 98: 1635-42. PMID 14534879 DOI: 10.1002/cncr.11711  0.123
2000 Wu XX, Kakehi Y, Takahashi T, Habuchi T, Ogawa O. Telomerase activity in urine after transurethral resection of superficial bladder cancer and early recurrence. International Journal of Urology : Official Journal of the Japanese Urological Association. 7: 210-7. PMID 10843452 DOI: 10.1046/j.1442-2042.2000.00178.x  0.123
2004 Wu XX, Ogawa O, Kakehi Y. Sensitization of human renal cell carcinoma cell lines to TRAIL-induced apoptosis by anthracyclines. International Journal of Urology : Official Journal of the Japanese Urological Association. 11: 164-70. PMID 15009365 DOI: 10.1111/j.1442-2042.2003.00766.x  0.123
2019 Hida T, Yamasaki T, Banno H, Fuchigami Y, Hattahara K, Fujiwara M, Suzuki R, Kita Y, Yoshino T, Goto T, Sawada A, Akamatsu S, Saito R, Kobayashi T, Inoue T, ... Ogawa O, et al. [Clinical Effect of Nivolumab on Advanced Renal Cell Carcinoma with Peritoneal Metastasis]. Hinyokika Kiyo. Acta Urologica Japonica. 65: 413-419. PMID 31697887 DOI: 10.14989/ActaUrolJap_65_10_413  0.123
2014 Kobayashi T, Ogawa O, Abate-Shen C. Abstract 1575: ARF regulates the stability of p16 protein via REGγ-dependent proteasome degradation Cancer Research. 74: 1575-1575. DOI: 10.1158/1538-7445.Am2014-1575  0.123
2020 Kanno T, Inoue T, Ito K, Okumura K, Yamada H, Kawakita M, Fujii M, Shimizu Y, Yatsuda J, Moroi S, Shichiri Y, Akao T, Sawada A, Kobayashi T, Ogawa O. Oncological outcomes and recurrence patterns after laparoscopic radical cystectomy for bladder cancer: A Japanese multicenter cohort. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 31944410 DOI: 10.1111/iju.14182  0.122
2003 Kobayashi T, Nakamura E, Yamamoto S, Kamoto T, Okuno H, Terai A, Kakehi Y, Terachi T, Fujikawa K, Fukuzawa S, Takeuchi H, Ogawa O. Low incidence of ipsilateral adrenal involvement and recurrences in patients with renal cell carcinoma undergoing radical nephrectomy: a retrospective analysis of 393 patients. Urology. 62: 40-5. PMID 12837419 DOI: 10.1016/S0090-4295(03)00247-4  0.122
2015 Inoue T, Ogura K, Kawakita M, Tsukino H, Akamatsu S, Yamasaki T, Matsui Y, Segawa T, Sugino Y, Kamoto T, Kamba T, Tanaka S, Ogawa O. Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. PMID 26433627 DOI: 10.1016/j.clgc.2015.08.008  0.122
2013 Saito R, Shirakawa R, Nishiyama H, Kobayashi T, Kawato M, Kanno T, Nishizawa K, Matsui Y, Ohbayashi T, Horiguchi M, Nakamura T, Ikeda T, Yamane K, Nakayama E, Nakamura E, ... ... Ogawa O, et al. Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer. Oncogene. 32: 894-902. PMID 22450745 DOI: 10.1038/onc.2012.101  0.122
2014 Mizuno T, Fukudo M, Fukuda T, Terada T, Dong M, Kamba T, Yamasaki T, Ogawa O, Katsura T, Inui K, Vinks AA, Matsubara K. The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma. Therapeutic Drug Monitoring. 36: 310-6. PMID 24825438 DOI: 10.1097/FTD.0000000000000025  0.121
2019 Goto T, Inoue T, Kobayashi T, Yamasaki T, Ishitoya S, Segawa T, Ito N, Shichiri Y, Okumura K, Okuno H, Kawakita M, Kanaoka T, Terada N, Mukai S, Sugi M, ... ... Ogawa O, et al. Feasibility of laparoscopic adrenalectomy for metastatic adrenal tumors in selected patients: a retrospective multicenter study of Japanese populations. International Journal of Clinical Oncology. PMID 31471786 DOI: 10.1007/s10147-019-01533-8  0.121
2001 Wu XX, Kakehi Y, Mizutani Y, Lu J, Terachi T, Ogawa O. Activation of caspase-3 in renal cell carcinoma cells by anthracyclines or 5-fluorouracil. International Journal of Oncology. 19: 19-24. PMID 11408917 DOI: 10.3892/IJO.19.1.19  0.121
2006 Tsuchiya N, Mishina M, Narita S, Kumazawa T, Inoue T, Horikawa Y, Kakinuma H, Yuasa T, Matsuura S, Satoh S, Ogawa O, Habuchi T. Association of XRCC1 gene polymorphisms with the susceptibility and chromosomal aberration of testicular germ cell tumors. International Journal of Oncology. 28: 1217-23. PMID 16596238  0.121
2021 Kubota M, Kanno T, Inoue T, Yamasaki T, Okumura K, Ito K, Yamada H, Fujii M, Shimizu Y, Yatsuda J, Moroi S, Shichiri Y, Akao T, Sawada A, Saito R, ... ... Ogawa O, et al. Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: A matched-pair analysis in a multicenter cohort. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 33682243 DOI: 10.1111/iju.14533  0.121
2001 YUASA T, OKAMOTO K, KAWAKAMI T, MISHINA M, OGAWA O, OKADA Y. EXPRESSION PATTERNS OF CANCER TESTIS ANTIGENS IN TESTICULAR GERM CELL TUMORS AND ADJACENT TESTICULAR TISSUE Journal of Urology. 165: 1790-1794. DOI: 10.1016/S0022-5347(05)66415-4  0.121
2011 Mizuno T, Fukudo M, Terada T, Kamba T, Nakamura E, Ogawa O, Inui K, Katsura T. Association of sunitinib pharmacokinetics with toxicity and genetic polymorphism in efflux transporter ABCG2 in patients with renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e15030. PMID 28020384 DOI: 10.1200/jco.2011.29.15_suppl.e15030  0.12
2004 Okada Y, Nishiyama H, Nakashima M, Ito N, Kinoshita H, Yamamoto S, Kamoto T, Ogawa O. [A case of vaginal metastasis of transitional cell carcinoma]. Hinyokika Kiyo. Acta Urologica Japonica. 50: 283-6. PMID 15188625  0.12
2008 Yoshimura K, Kamoto T, Okada T, Kawakita M, Ikeda H, Hayashi T, Yamamoto M, Kanamaru H, Masui K, Okuno H, Aoyama T, Terai A, Higashi S, Nishio Y, Ishitoya S, ... ... Ogawa O, et al. [Multi-institute survey on actual conditions of urologic management for severe bladder dysfunction after hysterectomy]. Hinyokika Kiyo. Acta Urologica Japonica. 54: 401-5. PMID 18634434  0.12
2016 Matsui Y, Ogawa O, Ishitsuka R, Miyazaki J, Inoue T, Kageyama S, Sugimoto M, Mitsuzuka K, Shiraishi Y, Kinoshita H, Wakeda H, Nomoto T, Kikuchi E, Fujie K, Keino N, et al. Current status of systemic chemotherapy for octogenarians with advanced urothelial cancer in Japan: a Japanese multi-institutional study (CURE study). International Journal of Clinical Oncology. PMID 27349431 DOI: 10.1007/s10147-016-1007-8  0.12
1993 Habuchi T, Ogawa O, Kakehi Y, Ogura K, Koshiba M, Hamazaki S, Takahashi R, Sugiyama T, Yoshida O. Accumulated allelic losses in the development of invasive urothelial cancer. International Journal of Cancer. 53: 579-84. PMID 8094713 DOI: 10.1002/IJC.2910530409  0.12
2004 Takahashi A, Tsukamoto T, Tobisu K, Shinohara N, Sato K, Tomita Y, Komatsubara S, Nishizawa O, Igarashi T, Fujimoto H, Nakazawa H, Komatsu H, Sugimura Y, Ono Y, Kuroda M, ... Ogawa O, et al. Radical cystectomy for invasive bladder cancer: results of multi-institutional pooled analysis. Japanese Journal of Clinical Oncology. 34: 14-9. PMID 15020658 DOI: 10.1093/JJCO/HYH005  0.119
1999 Sato K, Tsuchiya N, Sasaki R, Shimoda N, Satoh S, Ogawa O, Kato T. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Japanese Journal of Cancer Research : Gann. 90: 874-9. PMID 10543260 DOI: 10.1111/j.1349-7006.1999.tb00829.x  0.119
2016 Kono Y, Terada N, Takashima Y, Hikami K, Hida T, Goto S, Sunada T, Okada Y, Shibasaki N, Negoro H, Kobayashi T, Yamasaki T, Matsui Y, Inoue T, Kamba T, ... Ogawa O, et al. [Advanced Adenocarcinoma of the Bladder after Augmentation Gastrocystoplasty]. Hinyokika Kiyo. Acta Urologica Japonica. 62: 33-7. PMID 26932334  0.119
2003 Kawakami T, Okamoto K, Ogawa O, Okada Y. Multipoint methylation and expression analysis of tumor suppressor genes in human renal cancer cells. Urology. 61: 226-30. PMID 12559313 DOI: 10.1016/S0090-4295(02)02110-6  0.119
2018 Negoro H, Matsui Y, Nakayama T, Hatayama H, Ogawa O, Ichioka K. Sperm cryopreservation: Clinical and fertility outcomes in male oncological patients with germ cell tumors or hematological disorders. Reproductive Medicine and Biology. 17: 500-503. PMID 30377406 DOI: 10.1002/rmb2.12246  0.119
2004 Kawanishi H, Watanabe J, Ito M, Takahashi T, Kamoto T, Ogawa O, Nishiyama H. 738: Low-Level Expression of EphA2 is Associated with P53 Mutations and Intravesical Recurrence in Bladder Cancer Journal of Urology. 171: 196-196. DOI: 10.1016/s0022-5347(18)37987-4  0.119
2019 Kita Y, Hamada A, Saito R, Teramoto Y, Tanaka R, Takano K, Nakayama K, Murakami K, Matsumoto K, Akamatsu S, Yamasaki T, Inoue T, Tabata Y, Okuno Y, Ogawa O, et al. Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies. British Journal of Cancer. PMID 31673101 DOI: 10.1038/s41416-019-0609-0  0.118
2021 Suwa T, Kobayashi M, Shirai Y, Nam JM, Tabuchi Y, Takeda N, Akamatsu S, Ogawa O, Mizowaki T, Hammond EM, Harada H. SPINK1 as a plasma marker for tumor hypoxia and a therapeutic target for radiosensitization. Jci Insight. 6. PMID 34747365 DOI: 10.1172/jci.insight.148135  0.118
2012 Kanno T, Kamba T, Yamasaki T, Shibasaki N, Saito R, Terada N, Toda Y, Mikami Y, Inoue T, Kanematsu A, Nishiyama H, Ogawa O, Nakamura E. JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma. Oncogene. 31: 3098-110. PMID 22020339 DOI: 10.1038/onc.2011.475  0.118
2016 Fukui T, Matsui Y, Umeoka S, Inoue T, Kamba T, Togashi K, Ogawa O, Kobayashi T. Predictive value of radiological response rate for pathological response to neoadjuvant chemotherapy and post-cystectomy survival of bladder urothelial cancer. Japanese Journal of Clinical Oncology. PMID 26962244 DOI: 10.1093/jjco/hyw025  0.118
1994 Okamoto K, Toyokuni S, Uchida K, Ogawa O, Takenewa J, Kakehi Y, Kinoshita H, Hattori-Nakakuki Y, Hiai H, Yoshida O. Formation of 8-hydroxy-2'-deoxyguanosine and 4-hydroxy-2-nonenal-modified proteins in human renal-cell carcinoma. International Journal of Cancer. 58: 825-9. PMID 7523311 DOI: 10.1002/IJC.2910580613  0.118
2007 Nishiyama H, Matsui Y, Watanabe J, Kamoto T, Ogawa O. POS-02.09: Triptolide (PG490)-mediated sensitization of urothelial cancer cells to cisplatin via the interaction between glycogen synthase kinase-3β and p53 Urology. 70: 235. DOI: 10.1016/J.UROLOGY.2007.06.749  0.117
2013 Matsui Y, Nishiyama H, Yoshimura K, Xing ND, Sumiyoshi T, Saito R, Inoue T, Kamba T, Ogawa O. The effect of gemcitabine/paclitaxel chemotherapy on the survival of patients with metastatic urothelial cancers. International Journal of Clinical Oncology. 18: 321-8. PMID 22410820 DOI: 10.1007/s10147-012-0381-0  0.117
1997 Kinoshita H, Ogawa O, Mitsumori K, Kakehi Y, Terachi T, Yoshida O. Low frequency of positive telomerase activity in a chromophobe subtype of renal cell carcinoma. The Journal of Urology. 159: 245-51. PMID 9400489 DOI: 10.1016/S0022-5347(01)64076-X  0.117
2017 Negoro H, Ito K, Sawada A, Akamatsu S, Saito R, Kobayashi T, Terada N, Yamasaki T, Inoue T, Kamba T, Ogawa O. MP02-12 INTRAVESICAL PROSTATIC PROTRUSION IS NOT THE SAME IN ITS SHAPE: EVALUATION BY PREOPERATIVE CYSTOSCOPY AND OUTCOME IN HOLEP Journal of Urology. 197. DOI: 10.1016/j.juro.2017.02.108  0.117
2004 Yu J, Habuchi T, Tsuchiya N, Nakamura E, Kakinuma H, Horikawa Y, Inoue T, Ogawa O, Kato T. Association of the cyclin D1 gene G870A polymorphism with susceptibility to sporadic renal cell carcinoma. The Journal of Urology. 172: 2410-3. PMID 15538282 DOI: 10.1097/01.JU.0000138156.24384.16  0.117
2018 Aizawa R, Takayama K, Nakamura K, Inoue T, Kobayashi T, Akamatsu S, Yamasaki T, Ogawa O, Mizowaki T. Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for Japanese patients with non-metastatic prostate cancer. Journal of Clinical Oncology. 36: 49-49. DOI: 10.1200/JCO.2018.36.6_SUPPL.49  0.117
2020 Imai K, Yamasaki T, Sakamoto H, Nakamura K, Mizowaki T, Ogawa O, Aoyama T. [A Case of Primary Ewing Sarcoma of the Kidney Treated with Multidisciplinary Approach]. Hinyokika Kiyo. Acta Urologica Japonica. 66: 297-302. PMID 32988166 DOI: 10.14989/ActaUrolJap_66_9_297  0.116
2021 Suzuki R, Goto T, Banno H, Fuchigami Y, Hattahara K, Hida T, Fujiwara M, Yoshino T, Kita Y, Sawada A, Akamatsu S, Saito R, Kobayashi T, Yamazaki T, Inoue T, ... ... Ogawa O, et al. [A Case of Pelvic Unicentric Castleman Disease Treated by Preoperative Transcatheter Arterial Embolization and Tumor Complete Resection with Combined Lower Abdominal and Posterior Approach]. Hinyokika Kiyo. Acta Urologica Japonica. 67: 157-162. PMID 34107612 DOI: 10.14989/ActaUrolJap_67_4_157  0.116
2020 Sato Y, Boor P, Fukuma S, Klinkhammer BM, Haga H, Ogawa O, Floege J, Yanagita M. Developmental stages of tertiary lymphoid tissue reflect local injury and inflammation in mouse and human kidneys. Kidney International. PMID 32473779 DOI: 10.1016/j.kint.2020.02.023  0.116
2013 Kikuchi D, Iizuka T, Hoteya S, Yamada A, Furuhata T, Yamashita S, Domon K, Nakamura M, Matsui A, Mitani T, Ogawa O, Watanabe S, Kaise M. Usefulness of magnifying endoscopy with narrow-band imaging for determining tumor invasion depth in early gastric cancer. Gastroenterology Research and Practice. 2013: 217695. PMID 23401676 DOI: 10.1155/2013/217695  0.116
2020 Sakamoto H, Yamasaki T, Sumiyoshi T, Takeda M, Shibasaki N, Utsunomiya N, Arakaki R, Akamatsu S, Kobayashi T, Inoue T, Kamba T, Nakamura E, Ogawa O. Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma. Cancer Medicine. PMID 33107222 DOI: 10.1002/cam4.3578  0.116
2014 Hamada A, Yamasaki T, Negoro H, Kobayashi T, Terada N, Sugino Y, Matsui Y, Inoue T, Kamba T, Yoshimura K, Ogawa O. [Presurgical treatment of axitinib reduced operation risk by downsizing the vena cava tumor thrombus in advanced renal cell carcinomas: two case reports]. Hinyokika Kiyo. Acta Urologica Japonica. 60: 621-6. PMID 25602478  0.115
2021 Kato T, Hirama H, Mitsuzuka K, Maruyama S, Sasaki H, Saito T, Matsumoto R, Sakamoto S, Sakai Y, Fukuhara H, Naya Y, Tsukino H, Hara I, Ogawa O, Hashine K, et al. Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN. Prostate Cancer and Prostatic Diseases. PMID 34253849 DOI: 10.1038/s41391-021-00422-4  0.115
2016 Sato Y, Mii A, Hamazaki Y, Fujita H, Nakata H, Masuda K, Nishiyama S, Shibuya S, Haga H, Ogawa O, Shimizu A, Narumiya S, Kaisho T, Arita M, Yanagisawa M, et al. Heterogeneous fibroblasts underlie age-dependent tertiary lymphoid tissues in the kidney. Jci Insight. 1: e87680. PMID 27699223 DOI: 10.1172/jci.insight.87680  0.115
2011 Ogawa O. Asian School of Urology, Young Leaders' Workshop, Kyoto 2010. International Journal of Urology : Official Journal of the Japanese Urological Association. 18: 87-91. PMID 21198942 DOI: 10.1111/j.1442-2042.2010.02659.x  0.114
2022 Hattori Y, Kono J, Yoshino T, Masui K, Sato T, Kashima S, Sano T, Goto T, Sawada A, Akamatsu S, Kobayashi T, Inoue T, Ogawa O. [Diagnostic Accuracy of Transperineal MRI-Ultrasound Fusion Biopsy at the Introduction Period]. Hinyokika Kiyo. Acta Urologica Japonica. 68: 99-105. PMID 35613897 DOI: 10.14989/ActaUrolJap_68_4_99  0.114
2008 Masui K, Kamba T, Watanabe J, Soda T, Yoshimura K, Kanematsu A, Nakamura E, Nishiyama H, Ito N, Kamoto T, Ogawa O. [A case of small cell carcinoma of the ureter]. Hinyokika Kiyo. Acta Urologica Japonica. 54: 411-3. PMID 18634436  0.114
1996 Mishina M, Ogawa O, Kinoshita H, Oka H, Okumura K, Mitsumori K, Kakehi Y, Reeve AE, Yoshida O. Equivalent parental distribution of frequently lost alleles and biallelic expression of the H19 gene in human testicular germ cell tumors. Japanese Journal of Cancer Research : Gann. 87: 816-23. PMID 8797887 DOI: 10.1111/j.1349-7006.1996.tb02105.x  0.114
2003 Wu XX, Kakehi Y, Nishiyama H, Habuchi T, Ogawa O. Telomerase activity in urine after transurethral resection is not a predictive marker for recurrence of superficial bladder cancer. International Journal of Urology : Official Journal of the Japanese Urological Association. 10: 117-8. PMID 12588612 DOI: 10.1046/J.1442-2042.2003.00581.X  0.114
2021 Ito K, Kobayashi T, Kojima T, Hikami K, Yamada T, Ogawa K, Nakamura K, Sassa N, Yokomizo A, Abe T, Tsuchihashi K, Tatarano S, Inokuchi J, Tomida R, Fujiwara M, ... ... Ogawa O, et al. Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort. Cancer Medicine. PMID 33931987 DOI: 10.1002/cam4.3863  0.113
2015 Akiyama S, Kikuchi D, Mitani T, Fujii T, Yamada A, Matsui A, Ogawa O, Iizuka T, Hoteya S, Kaise M. A case of mucinous adenocarcinoma in the setting of chronic colitis associated with intestinal spirochetosis and intestinal stricture. Medicine. 94: e493. PMID 25634199 DOI: 10.1097/MD.0000000000000493  0.113
2013 Hoteya S, Matsui A, Iizuka T, Kikuchi D, Yamada A, Yamashita S, Furuhata T, Domon K, Nakamura M, Mitani T, Ogawa O, Kasie M. Comparison of the clinicopathological characteristics and results of endoscopic submucosal dissection for esophagogastric junction and non-junctional cancers. Digestion. 87: 29-33. PMID 23343966 DOI: 10.1159/000343934  0.113
2012 Kita Y, Inoue T, Shimizu Y, Kamba T, Yoshimura K, Ogawa O. [Subclassification of the D'Amico's high risk group to predict biochemical recurrence after radical prostatectomy]. Hinyokika Kiyo. Acta Urologica Japonica. 58: 319-24. PMID 22895126  0.113
2001 Habuchi T, Takahashi T, Kakinuma H, Wang L, Tsuchiya N, Satoh S, Akao T, Sato K, Ogawa O, Knowles MA, Kato T. Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. Oncogene. 20: 531-7. PMID 11313984 DOI: 10.1038/sj.onc.1204122  0.113
2011 Masui K, Yoshimura K, Nishiyama H, Okuno H, Ogawa O. Transition in Type of Surgery for Benign Prostatic Hyperplasia: A Multi-institutional Study in Japan. Lower Urinary Tract Symptoms. 3: 104-8. PMID 26676395 DOI: 10.1111/j.1757-5672.2011.00093.x  0.112
2011 Masui K, Yoshimura K, Nishiyama H, Okuno H, Ogawa O. Transition in Type of Surgery for Benign Prostatic Hyperplasia: A Multi-institutional Study in Japan. Lower Urinary Tract Symptoms. 3: 104-8. PMID 26676395 DOI: 10.1111/j.1757-5672.2011.00093.x  0.112
1999 Ohgaki K, Minobe K, Kurose K, Iida A, Habuchi T, Ogawa O, Kubota Y, Akimoto M, Emi M. Two target regions of allelic loss on chromosome 9 in urinary-bladder cancer. Japanese Journal of Cancer Research : Gann. 90: 957-64. PMID 10551324 DOI: 10.1111/j.1349-7006.1999.tb00841.x  0.112
2009 Ichioka K, Nagahama K, Okubo K, Soda T, Ogawa O, Nishiyama H. Genetic polymorphisms in glutathione S-transferase T1 affect the surgical outcome of varicocelectomies in infertile patients. Asian Journal of Andrology. 11: 333-41. PMID 19151739 DOI: 10.1038/aja.2008.27  0.112
2007 Imamura M, Kanematsu A, Yamamoto S, Kimura Y, Kanatani I, Ito N, Tabata Y, Ogawa O. Basic fibroblast growth factor modulates proliferation and collagen expression in urinary bladder smooth muscle cells. American Journal of Physiology. Renal Physiology. 293: F1007-17. PMID 17634401 DOI: 10.1152/ajprenal.00107.2007  0.112
2007 Tsuchiya N, Fukuda H, Narita S, Kumazawa T, Horikawa Y, Inoue T, Saito M, Yuasa T, Matsuura S, Satoh S, Ogawa O, Habuchi T. 155: Clinical Implication of Vascular Endothelial Growth Factor (VEGF) T-460c Polymorphism in the Risk and Progression of Prostate Cancer Journal of Urology. 177: 53-53. DOI: 10.1016/S0022-5347(18)30420-8  0.112
2020 Kashima S, Maeda T, Masuda K, Nagano S, Inoue T, Takeda M, Kono Y, Kobayashi T, Saito S, Higuchi T, Ichise H, Kobayashi Y, Iwaisako K, Terada K, Agata Y, ... ... Ogawa O, et al. Cytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model. Iscience. 100998. PMID 32259478 DOI: 10.1016/j.isci.2020.100998  0.112
2020 Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. The Lancet. Oncology. PMID 32971005 DOI: 10.1016/S1470-2045(20)30541-6  0.112
2001 Kakinuma H, Habuchi T, Ito T, Mishina M, Sato K, Satoh S, Akao T, Ogawa O, Kato T. BCL10 is not a major target for frequent loss of 1p in testicular germ cell tumors. Cancer Genetics and Cytogenetics. 126: 134-8. PMID 11376806 DOI: 10.1016/S0165-4608(00)00405-2  0.111
2006 Kamoto T, Nishiyama H, Kawahara T, Higashi S, Takahashi T, Ito N, Ogawa O. S14-5 Management of high risk superficial bladder cancer : the timing of radical cystectomy(Symposium 14「Management of Superficial Bladder Cancer」) The Japanese Journal of Urology. 97: 179. DOI: 10.5980/jpnjurol.97.179  0.111
2005 Kobayashi T, Nakamura E, Ogura K, Ogawa O. Incidence of adrenal involvement and assessing adrenal function in patients with renal cell carcinoma: is ipsilateral adrenalectomy indispensable during radical nephrectomy? Bju International. 96: 916. PMID 16153232 DOI: 10.1111/j.1464-410X.2005.05841_2.x  0.111
2020 Somiya S, Aoyama A, Yamasaki T, Inoue T, Ogawa O, Kobayashi T. Successful surgical management of recurrent urachal adenocarcinoma: A case report. Urology Case Reports. 32: 101196. PMID 32322529 DOI: 10.1016/j.eucr.2020.101196  0.111
2014 Takeda M, Kobayashi T, Sumiyoshi S, Okubo K, Negoro H, Miyata H, Terada N, Sugino Y, Yamasaki T, Matsui Y, Inoue T, Kamba T, Yoshimura K, Ogawa O. [A case of successful living related renal transplantation in a patient with end-stage renal disease resulting from sarcoidosis]. Hinyokika Kiyo. Acta Urologica Japonica. 60: 319-22. PMID 25142957  0.111
2006 Matsui Y, Kawanishi H, Ito M, Watanabe J, Nishiyama H, Ogawa O, Ueda S, Kuwabara I, Liu F. 644: Impact of Galectin 7 Expression on the Chemosensitivity of Urothelial Cancer The Journal of Urology. 175: 207-207. DOI: 10.1016/S0022-5347(18)32890-8  0.111
2013 Takaoka E, Matsui Y, Inoue T, Miyazaki J, Nakashima M, Kimura T, Oikawa T, Kawai K, Yoshimura K, Habuchi T, Ogawa O, Nishiyama H. Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era. Japanese Journal of Clinical Oncology. 43: 404-9. PMID 23444116 DOI: 10.1093/jjco/hyt016  0.11
2021 Kobayashi T, Ito K, Kojima T, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, Shimazui T, Segawa T, Karashima T, Masui K, Fukuta F, ... ... Ogawa O, et al. Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR. Cancer Immunology, Immunotherapy : Cii. PMID 34235546 DOI: 10.1007/s00262-021-03000-8  0.11
2002 Wang L, Habuchi T, Takahashi T, Kamoto T, Zuo T, Mitsumori K, Tsuchiya N, Sato K, Ogawa O, Kato T. No association between HER-2 gene polymorphism at codon 655 and a risk of bladder cancer. International Journal of Cancer. 97: 787-90. PMID 11857355 DOI: 10.1002/ijc.10129  0.11
2019 Ueda M, Sengiku A, Kono J, Negoro H, Saito R, Yoshimura N, Ogawa O, Ueda T. Low bladder capacity is an important predictor for comorbidity of interstitial cystitis with Hunner's lesion in patients with refractory chronic prostatitis/chronic pelvic pain syndrome. International Journal of Urology : Official Journal of the Japanese Urological Association. 26: 53-56. PMID 31144759 DOI: 10.1111/iju.13975  0.11
2012 Yamasaki T, Kamba T, Kanno T, Inoue T, Shibasaki N, Arakaki R, Yamada T, Kondo K, Kamoto T, Nishiyama H, Ogawa O, Nakamura E. Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy. Cancer Science. 103: 2027-37. PMID 22931246 DOI: 10.1111/j.1349-7006.2012.02412.x  0.11
2012 Mizuno T, Fukudo M, Terada T, Kamba T, Nakamura E, Ogawa O, Inui K, Katsura T. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics. Drug Metabolism and Pharmacokinetics. 27: 631-9. PMID 22673043 DOI: DN/JST.JSTAGE/dmpk/DMPK-12-RG-026  0.109
2020 Yamashita S, Suzukamo Y, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura T, Goto T, Osawa T, Yamada S, Nishimura K, Nonomura N, Nishiyama H, Shiraishi T, Ukimura O, ... Ogawa O, et al. Validation study of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 for patients with testicular cancer. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 33174259 DOI: 10.1111/iju.14422  0.109
2011 Goto T, Yoshimura K, Matsui Y, Shimizu Y, Inoue T, Okubo K, Kamba T, Nishiyama H, Ogawa O. [Impact of different methods of estimating renal function on determining eligibility for cisplatin (CDDP)-based chemotherapy in patients with invasive urothelial carcinoma]. Hinyokika Kiyo. Acta Urologica Japonica. 57: 671-6. PMID 22240299  0.109
2011 Sumiyoshi T, Shimizu Y, Inoue T, Okubo K, Watanabe J, Kamba T, Yoshimura K, Kanematsu A, Nakamura E, Nishiyama H, Kamoto T, Sumiyoshi S, Ogawa O. [A case of renal cell carcinoma associated with paraganglioma]. Hinyokika Kiyo. Acta Urologica Japonica. 57: 429-33. PMID 21894079  0.108
2005 Okada Y, Yamamoto S, Akamatsu S, Kanamaru S, Ito N, Kinoshita H, Kamoto T, Ogawa O. [Primary transitional carcinoma of the remaining ureter after nephrectomy for pyonephrosis: a case report]. Hinyokika Kiyo. Acta Urologica Japonica. 51: 101-3. PMID 15773362  0.108
2016 Sano T, Kobayashi T, Negoro H, Sengiku A, Hiratsuka T, Kamioka Y, Liou LS, Ogawa O, Matsuda M. Intravital imaging of mouse urothelium reveals activation of extracellular signal-regulated kinase by stretch-induced intravesical release of ATP. Physiological Reports. 4. PMID 27905300 DOI: 10.14814/phy2.13033  0.108
2015 Nakamura K, Terada N, Kobayashi T, Sugino Y, Yamasaki T, Matsui Y, Imamura M, Okubo K, Kamba T, Yoshimura K, Ogawa O. Clinical characteristics of prostate ductal adenocarcinoma in Kyoto University Hospital Acta Urologica Japonica. 61: 487-491.  0.108
2005 Niu Z, Ito M, Awakura Y, Takahashi T, Nakamura E, Ito N, Ogawa O. The expression of NOV and WT1 in renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis. The Journal of Urology. 174: 1460-2. PMID 16145471  0.108
2015 Sunada T, Kobayashi T, Matsui Y, Inoue T, Kamba T, Ogawa O. MP5-03 ADHERENCE AND ADEQUACY OF THE BLADDER CANCER GUIDELINES FOR POST-TUR FOLLOW-UP INTERVAL Journal of Urology. 193. DOI: 10.1016/j.juro.2015.02.230  0.108
2013 Murakami K, Kobayashi T, Okubo K, Kamba T, Yoshimura K, Ogawa O. Successful renal transplantation for end-stage renal insufficiency developed in a patient with Castleman's disease. Transplant International : Official Journal of the European Society For Organ Transplantation. 26: e61-2. PMID 23560690 DOI: 10.1111/tri.12099  0.108
2014 Matsumoto K, Takashi K, Negoro H, Terada N, Sugino Y, Yamasaki T, Matsui Y, Inoue T, Kanba T, Yoshimura K, Ogawa O. 1102 Guideline adherence of immediate post-TUR intravesical chemotherapy for patients with non-muscle invasive bladder cancer European Urology Supplements. 13: e1102-e1102b. DOI: 10.1016/S1569-9056(14)61082-4  0.107
2015 Nakashima M, Matsui Y, Kobayashi T, Saito R, Hatahira S, Kawakami K, Nakamura E, Nishiyama H, Ogawa O. Urine CXCL1 as a biomarker for tumor detection and outcome prediction in bladder cancer. Cancer Biomarkers : Section a of Disease Markers. 15: 357-64. PMID 26406865 DOI: 10.3233/CBM-150472  0.107
2000 Higashi S, Habuchi T, Takahashi T, Kamoto T, Kakehi Y, Ogawa O, Hiai H. Allelic imbalances on chromosome 20 in human transitional cell carcinoma. Japanese Journal of Cancer Research : Gann. 91: 499-503. PMID 10835494 DOI: 10.1111/j.1349-7006.2000.tb00973.x  0.107
2010 Mizuno T, Terada T, Kamba T, Fukudo M, Katsura T, Nakamura E, Ogawa O, Inui K. Association of ABCG2 polymorphisms with exposure and toxicity of sunitinib in a patient with renal cell carcinoma. Journal of Clinical Oncology. 28: e15037-e15037. DOI: 10.1200/jco.2010.28.15_suppl.e15037  0.107
2009 Shiraishi Y, Nishiyama H, Okubo K, Iguchi R, Inoue T, Watanabe J, Kamba T, Yoshimura K, Kanematsu A, Nakayama T, Hatayama H, Ogawa O. [Testicular Leydig cell tumor presenting as male infertility: a case report]. Hinyokika Kiyo. Acta Urologica Japonica. 55: 777-81. PMID 20048565  0.106
2012 Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S. Use of STAT3 polymorphisms to predict overall survival in patients treated with interferon-alpha for metastatic renal cell carcinoma. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E15048  0.106
2006 Akamatsu S, Kinoshita H, Shimizu Y, Yoshimura K, Ito N, Kamoto T, Ogawa O. Retroperitoneoscopic nephrectomy as a second-line treatment after transarterial embolization for symptomatic autosomal dominant polycystic kidney disease. Hinyokika Kiyo. Acta Urologica Japonica. 52: 947-50. PMID 17252979  0.106
2007 Inoue T, Nishiyama H, Yoshimura K, Ito N, Kamoto T, Habuchi T, Ogawa O. Solitary upper ureteral malakoplakia successfully diagnosed by ureteroscopic biopsy and treated conservatively. International Journal of Urology : Official Journal of the Japanese Urological Association. 14: 859-61. PMID 17760757 DOI: 10.1111/j.1442-2042.2007.01825.x  0.106
2004 Ichimura Y, Habuchi T, Tsuchiya N, Wang L, Oyama C, Sato K, Nishiyama H, Ogawa O, Kato T. Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant. The Journal of Urology. 172: 728-32. PMID 15247771 DOI: 10.1097/01.JU.0000130942.40597.9D  0.106
1994 Habuchi T, Kinoshita H, Yamada H, Kakehi Y, Ogawa O, Wu WJ, Takahashi R, Sugiyama T, Yoshida O. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. Journal of the National Cancer Institute. 86: 1331-5. PMID 8064891 DOI: 10.1093/JNCI/86.17.1331  0.106
2004 Kawakami T, Okamoto K, Ogawa O, Okada Y. XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. Lancet (London, England). 363: 40-2. PMID 14723995 DOI: 10.1016/S0140-6736(03)15170-7  0.106
2022 Suzuki R, Goto T, Yoshino T, Sawada A, Akamatsu S, Saito R, Kobayashi T, Yamasaki T, Inoue T, Kamba T, Ogawa O. [A Retrospective Study of Lymph Node Dissection for Renal Cell Carcinoma]. Hinyokika Kiyo. Acta Urologica Japonica. 68: 165-170. PMID 35850504 DOI: 10.14989/ActaUrolJap_68_6_165  0.106
2013 Nakamura K, Terada N, Shimizu Y, Kobayashi T, Sugino Y, Yamasaki T, Matsui Y, Imamura M, Okubo K, Kamba T, Yoshimura K, Ogawa O. [Pseudomyxoma peritonei arising from urachal carcinoma]. Hinyokika Kiyo. Acta Urologica Japonica. 59: 657-62. PMID 24262707  0.106
2020 Kobayashi T, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, ... ... Ogawa O, et al. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab. Cancer Science. PMID 33283385 DOI: 10.1111/cas.14762  0.106
2006 Kawanishi H, Takahashi T, Ito M, Watanabe J, Higashi S, Kamoto T, Habuchi T, Kadowaki T, Tsujimoto G, Nishiyama H, Ogawa O. High throughput comparative genomic hybridization array analysis of multifocal urothelial cancers. Cancer Science. 97: 746-52. PMID 16863508 DOI: 10.1111/j.1349-7006.2006.00259.x  0.106
2010 Tsutsumi N, Soda T, Shimizu T, Watanabe J, Yoshimura K, Kamba T, Kanematsu A, Nakamura E, Nishiyama H, Ito N, Kamoto T, Ogawa O. [Multiple chromophobe renal cell carcinoma: a case report]. Hinyokika Kiyo. Acta Urologica Japonica. 56: 319-21. PMID 20610924  0.106
2001 Takahashi T, Kakehi Y, Mitsumori K, Akao T, Terachi T, Kato T, Ogawa O, Habuchi T. Distinct microsatellite alterations in upper urinary tract tumors and subsequent bladder tumors. The Journal of Urology. 165: 672-7. PMID 11176456 DOI: 10.1097/00005392-200102000-00092  0.105
1999 Suzuki T, Tsuchiya N, Otomo R, Kakinuma H, Satoh S, Sato K, Ogawa O, Kato T. Primary tumor of the ureteral stump following a nephrectomy for renal cell carcinoma. International Journal of Urology : Official Journal of the Japanese Urological Association. 6: 41-3. PMID 10221864 DOI: 10.1046/j.1442-2042.1999.06124.x  0.105
2021 Hamada A, Sano T, Matsumoto K, Sakatani T, Nakamura K, Sawada A, Akamatsu S, Matsui Y, Ogawa O, Kobayashi T. Modification of Platinum-based Systemic Chemotherapy for Advanced Urothelial Carcinoma in Patients With Suboptimal Renal Function. In Vivo (Athens, Greece). 35: 2821-2829. PMID 34410974 DOI: 10.21873/invivo.12569  0.105
2019 Imai K, Inoue T, Saito R, Goto T, Sawada A, Akamatsu S, Negoro H, Kobayashi T, Terada N, Yamasaki T, Okubo K, Yoshimura K, Kanematsu A, Ogawa O. [A Case of Advanced Right Renal Pelvic Cancer with Left Supraclavicular Lymph Node Metastasis that Attained Long-Term Survival by Multidisciplinary Treatments]. Hinyokika Kiyo. Acta Urologica Japonica. 65: 13-17. PMID 30831672 DOI: 10.14989/ActaUrolJap_65_1_13  0.105
2013 Kohno J, Matsui Y, Yamasaki T, Shibasaki N, Kamba T, Yoshimura K, Sumiyoshi S, Mikami Y, Ogawa O. Role of mammalian target of rapamycin inhibitor in the treatment of metastatic epithelioid angiomyolipoma: a case report. International Journal of Urology : Official Journal of the Japanese Urological Association. 20: 938-41. PMID 23347205 DOI: 10.1111/iju.12095  0.105
2000 TERAI A, ISHITOYA S, MITSUMORI K, OGAWA O. MOLECULAR EPIDEMIOLOGICAL EVIDENCE FOR ASCENDING URETHRAL INFECTION IN ACUTE BACTERIAL PROSTATITIS Journal of Urology. 164: 1945-1947. DOI: 10.1016/S0022-5347(05)66925-X  0.105
2020 Ito K, Ichioka K, Dahal S, Matsui Y, Nakayama T, Hatayama H, Ogawa O, Negoro H. Barriers for sperm cryopreservation in advanced germ cell tumor patients: a 20-year experience. International Journal of Clinical Oncology. PMID 31894434 DOI: 10.1007/s10147-019-01607-7  0.104
2021 Hagimoto H, Yamazaki T, Kashima S, Yoshino T, Goto T, Sano T, Sawada A, Akamatsu S, Kobayashi T, Nakano K, Yagi S, Matsuoka Y, Fujimoto M, Kitamura T, Ogawa O. [Complete Remission of Metastatic Renal Cell Carcinoma with Invasion of the Duodenum and Pancreas after Treatment with Nivolumab Plus Ipilimumab Followed by Axitinib and Surgery : A Case Report]. Hinyokika Kiyo. Acta Urologica Japonica. 67: 197-203. PMID 34126663 DOI: 10.14989/ActaUrolJap_67_5_197  0.104
2017 Magaribuchi T, Akamatsu S, Kobayashi T, Kawabata H, Yamasaki T, Inoue T, Ogawa O. Safe and effective administration of BCG for bladder carcinoma in situ after umbilical cord blood stem cell transplantation. Transplant Infectious Disease : An Official Journal of the Transplantation Society. PMID 28796929 DOI: 10.1111/tid.12758  0.104
2017 Inoue T, Terada N, Kobayashi T, Ogawa O. Patient-derived xenografts as in vivo models for research in urological malignancies. Nature Reviews. Urology. PMID 28248952 DOI: 10.1038/nrurol.2017.19  0.104
1993 Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, Smith PJ, Reeve AE. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature. 362: 749-51. PMID 8097018 DOI: 10.1038/362749a0  0.104
2022 Kono J, Ueda M, Sengiku A, Suadicani SO, Woo JT, Kobayashi T, Ogawa O, Negoro H. Flavonoid Nobiletin Attenuates Cyclophosphamide-Induced Cystitis in Mice through Mechanisms That Involve Inhibition of IL-1β Induced Connexin 43 Upregulation and Gap Junction Communication in Urothelial Cells. International Journal of Molecular Sciences. 23. PMID 35563427 DOI: 10.3390/ijms23095037  0.103
1998 Kinoshita H, Ogawa O, Mishina M, Oka H, Okumura K, Yamabe H, Terachi T, Yoshida O. Telomerase activity in adrenal cortical tumors and pheochromocytomas with reference to clinicopathologic features. Urological Research. 26: 29-32. PMID 9537693 DOI: 10.1007/s002400050019  0.103
2014 Matsui Y, Kanematsu A, Negoro H, Kobayashi T, Terada N, Sugino Y, Yamasaki T, Inoue T, Kamba T, Yoshimura K, Ogawa O. [Urinary diversion in patients treated with pelvic irradiation: transverse colon conduit revisited]. Hinyokika Kiyo. Acta Urologica Japonica. 60: 365-70. PMID 25179985  0.103
2018 Saga T, Nakamoto Y, Ishimori T, Inoue T, Shimizu Y, Kimura H, Akamatsu S, Goto T, Watanabe H, Kitaguchi K, Watanabe M, Ono M, Saji H, Ogawa O, Togashi K. Initial evaluation of PET/CT with F-FSU-880 targeting prostate-specific membrane antigen in prostate cancer patients. Cancer Science. PMID 30549183 DOI: 10.1111/cas.13911  0.103
2017 Inokuchi J, Kuroiwa K, Kakehi Y, Sugimoto M, Tanigawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Ohyama C, Yamaguchi A, Matsuyama H, Ichikawa T, Asano T, et al. Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: multi-institutional large retrospective study JCOG1110A. World Journal of Urology. PMID 28508102 DOI: 10.1007/s00345-017-2049-x  0.103
Hide low-probability matches.